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HGF-MET AGONIST FOR USE IN THE TREATMENT OF CANCER
AND COLORECTAL FIBROSIS
FIELD OF THE INVENTION
The present invention relates to treatment of cancer using agonist anti-MET
antibodies or fragments thereof. In particular, the invention relates to treatment of colorectal
cancer using agonist anti-MET antibodies or fragments, typically colorectal cancer
associated with chronic inflammation and/or gene mutations in the colon and in the
gastrointestinal tract in general. The invention further relates to treating intestinal fibrosis
using agonist anti-MET antibodies.
BACKGROUND
HGF is a pleiotropic cytokine of mesenchymal origin that mediates a characteristic
array of biological functions including cell proliferation, motility, differentiation and survival.
The HGF receptor, also known as MET, is expressed by a variety of tissues including all
epithelia, the endothelium, muscle cells, neuronal cells, osteoblasts, hematopoietic cells and
various components of the immune system. HGF and MET signalling plays an essential role
during embryo development, where it guides migration of precursor cells and determines cell
survival or death.
In adults, HGF/MET signalling is ordinarily quiescent and is resumed during wound
healing and tissue regeneration. Some cancers and tumours hijack HGF/MET signalling in
order to promote the survival and proliferation of the tumour in the host organism.
Therefore, inhibiting the HGF-MET axis has become a popular target for anti-cancer
treatment. Use of an agonist of HGF-MET as an anti-cancer therapy has not previously been
demonstrated.
Colorectal cancer is the third most common cancer in terms of incidence, with a 5
year survival rate of approximately 65%. Subjects particularly at risk include those with
inflammatory bowel disease, or genetic predispositions (e.g. those with a history of hereditary
nonpolyposis colorectal cancer (HNPCC or Lynch syndrome), Gardner syndrome, or familial
adenomatous polyposis (FAP)). Treatment with surgery (e.g. colectomy) and/or
chemotherapy and radiotherapy can be effective, but lead to significant loss in standard of
living. There is therefore a need for effective therapies for colorectal cancer.
SUMMARY OF THE INVENTION
HGF is a known pro-oncogenic factor that plays a key role in tumorigenesis of various
tissues and organs, including the gastro-intestinal tract (Gherardi et at. Nat Rev Cancer
12:89-103, 2012; Vermeulen et al. Nat Cell Biol. 12:468-476, 2010; Samame Perez-Vargas
et al. Int J Mol Sci. 14:1 8056-1 8077, 2013; Stein et al. Nat Med. 15: 59-67, 2009, each of
which is incorporated herein by reference). As a result, inhibiting HGF-MET has become a
popular target for anti-cancer treatment. However, it is surprisingly identified herein that an
agonist of HGF-MET acts as an effective anti-cancer therapy.
Therefore, in a first aspect, the invention provides a method of treating cancer in a
subject, the method comprising administering to the subject an HGF-MET agonist. In certain
preferred embodiments, the HGF-MET agonist is an anti-MET agonist antibody or antigen
fragment thereof.
Surprisingly, an HGF-MET agonist (e.g. an anti-MET agonist antibody) is particularly
effective as a therapy for colorectal cancer, as demonstrated herein. Without wishing to be
bound by theory, it is hypothesised that stimulation of the HGF-MET signalling promotes
regeneration and homeostatic mechanisms of intestinal epithelial cells, thereby dampening
potentially oncogenic mechanisms (Nakamura et al., J Gastroenterol Hepatol. 1: 1 88-202,
201 1, incorporated herein by reference).
In a further aspect, the invention provides a method of treating colorectal fibrosis in a
subject, the method comprising administering to a subject an HGF-MET agonist.
Advantageously, it is also demonstrated herein that HGF-MET agonists are
surprisingly effective at treating colorectal cancer in inflamed guts. Further advantageously, it
is also demonstrated herein that HGF-MET agonists are surprisingly effective at treating
colorectal fibrosis in inflamed guts.
This is particularly advantageous since patients suffering from colorectal inflammation
are at increased risk of colorectal cancer and also from fibrosis. For instance, patients
suffering from inflammatory bowel disease (IBD; i.e. Crohn’s Disease or ulcerative colitis) are
predisposed to colorectal cancer and will advantageously benefit from the methods
described herein. Furthermore, HGF-MET agonists can also relieve the symptoms of the
underlying IBD itself. Therefore the methods of the invention will lead to a synergistic effect in
IBD patients whereby colorectal cancer in these patients can be treated and, furthermore, the
patient’s IBD is also treated. Similarly, the methods of the invention will lead to a synergistic
effect in IBD patients whereby colorectal fibrosis in these patients can be treated and,
furthermore, the patient’s IBD is also treated.
Therefore, in a further preferred embodiment, the method of the invention is a method
of treating colorectal cancer in a patient or subject identified as at increased risk of colorectal
cancer. In certain embodiments, the subject has been diagnosed with colorectal inflammation
prior to administration of the HGF-MET agonist. In certain embodiments of the methods
described herein, the subject has IBD (ulcerative colitis or Crohn’s Disease). In preferred
such embodiments, the HGF-MET agonist administered to the subject is an anti-MET agonist
antibody.
Similarly, in a further preferred embodiment, the method of the invention is a method
of treating colorectal fibrosis in a patient or subject identified as at increased risk of colorectal
fibrosis. In certain embodiments, the subject has been diagnosed with colorectal
inflammation prior to administration of the HGF-MET agonist. In certain embodiments of the
methods described herein, the subject has IBD (ulcerative colitis or Crohn’s Disease). In
preferred such embodiments, the HGF-MET agonist administered to the subject is an anti-
MET agonist antibody.
In a further aspect is provided an HGF-MET agonist for use in methods of treatment
of cancer (e.g. colorectal cancer) in a subject as described herein. In preferred such
embodiments, the HGF-MET agonist is an anti-MET agonist antibody or antigen fragment
thereof.
In a further aspect is provided an HGF-MET agonist for use in methods of treatment
of colorectal fibrosis in a subject as described herein. In preferred such embodiments, the
HGF-MET agonist is an anti-MET agonist antibody or antigen fragment thereof.
In a further aspect is provided a pharmaceutical composition for use in methods of
treating cancer (e.g. colorectal cancer) as described herein, wherein the pharmaceutical
composition comprises an HGF-MET agonist and a pharmaceutically acceptable excipient or
carrier. In preferred such embodiments, the HGF-MET agonist is an anti-MET agonist
antibody or antigen fragment thereof.
In a further aspect is provided a pharmaceutical composition for use in methods of
treating colorectal fibrosis as described herein, wherein the pharmaceutical composition
comprises an HGF-MET agonist and a pharmaceutically acceptable excipient or carrier. In
preferred such embodiments, the HGF-MET agonist is an anti-MET agonist antibody or
antigen fragment thereof.
In a preferred embodiment of all aspects of the invention, the subject or patient is a
human.
In a preferred embodiment of all aspects of the invention, the HGF-MET agonist is a
full agonist.
In a preferred embodiment of all aspects of the invention, the HGF-MET agonist is an
anti-MET agonist antibody.
DRAWINGS
Figure 1. AOM/DSS colon carcinogenesis model: body weight and disease
activity index (DAI) over time. Colitis-associated colorectal cancer was induced in BALB/c
mice by i.p. administration of azoxymethane (AOM) at a dose of 12,5 mg/kg followed by
three cycles of dextran sodium sulphate (DSS) in the drinking water at a concentration of 6%.
Each cycle consisted of 7 days of DSS treatment followed by 14 days of regular water.
Starting from day 1, mice were randomized into 4 arms which received treatment with: (i)
vehicle only (PBS); (ii) the MET agonistic 7 1D6 antibody at a dose of 1 mg/kg ; (iii) the MET
agonistic 7 1D6 antibody at a dose of 5 mg/kg; (iv) the MET antagonistic antibody 74C8-OA
at a dose of 5 mg/kg. An additional, fifth control arm contained 7 mice that received no
AOM-DSS or antibody and served as healthy control. Antibodies were delivered by i.p.
injection two times a week. During the whole course of the experiment, mouse weight was
monitored on a regular basis, and the clinical symptoms of ulcerative colitis were assessed
by determining fecal blood, rectal bleeding and stool consistency. Each parameter was given
a score from 0 (absence of the symptom) to 3 (maximal manifestation of the symptom).
Scores relative to the single parameters were summed together to give rise to the DAI
ranging from 0 to 9 . (A) Body weight over time. (B) DAI over time.
Figure 2. AOM/DSS colon carcinogenesis model: colon length and specific
weight. Colitis-associated cancer was induced in BALB/c mice as described in Figure 1
legend. At autopsy, colon specimens were collected and washed through. Tissues were
weighed and their length was determined using a ruler. (A) Colon length. (B) Colon specific
weight.
Figure 3. AOM/DSS colon carcinogenesis model: representative images of
intestinal tumours. Colitis-associated cancer was induced in BALB/c mice as described in
Figure 1 legend. At autopsy, colon specimens were collected and washed through. Following
length and weight measurement, colons were opened with a longitudinal cut and stained with
1% Alcian Blue solution to highlight tumour borders. Colon specimens were analyzed by
placing the flattened tissue under a stereo-microscope with their inner (lumen) side towards
the lens, and photographed. Magnification: 1X.
Figure 4. AOM/DSS colon carcinogenesis model: analysis of mean tumour
number, mean tumour volume and total tumour burden. Colitis-associated cancer was
induced in BALB/c mice as described in Figure 1 legend, and carcinogenesis was quantified
using a stereo-microscope. (A) Tumour number. The number of polips in each colon sample
was scored directly. (B) Mean tumour volume. Tumour photographs were analyzed using
Image J software (National Instututes of Health) and the volume of the polips was calculated
using the formula V = ¾ ( /2)·( /2)2, where V is the volume of the polip, and X and Y are
the major and minor dimensions of the polip section, respectively (in mm). (C) Total tumour
burden. Total tumour burden (volume) was calculated by multiplying the mean tumour
volume by the number of tumours in each mouse.
Figure 5. AOM/DSS colon carcinogenesis model: histological analysis of colon
samples. Colitis-associated cancer was induced in BALB/c mice as described in Figure 1
legend. Following tissue processing and paraffin embedding, colon specimens were cut
using a microtome and prepared for histological and immunohistochemical analysis. Here,
we show representative images of colon sections stained with hematoxylin and eosin.
Magnification: 100X.
Figure 6. AOM/DSS colon carcinogenesis model: immunohistochemical
analysis of collagen deposition. Colitis-associated cancer was induced in BALB/c mice as
described in Figure 1 legend. Colon sections were analyzed by immunohistochemistry. Here,
we show representative images of colon sections stained with picro-sirius red, which
highlights collagen deposition, a hallmark of tissue fibrosis. Magnification: 400X.
Figure 7. AOM/DSS colon carcinogenesis model: immunohistochemical
analysis of myofibroblast content. Colitis-associated cancer was induced in BALB/c mice
as described in Figure 1 legend. Colon sections were analyzed by immunohistochemistry.
Here, we show representative images of colon sections stained with anti-alpha smooth
muscle actin ( -SMA) antibodies, which specifically identify myofibroblasts. Myofibroblast
accumulation is a hallmark of fibrosis. Magnification: 400X.
Figure 8. AOM/DSS colon carcinogenesis model: immunohistochemical
analysis of TGF- expression. Colitis-associated cancer was induced in BALB/c mice as
described in Figure 1 legend. Colon sections were analyzed by immunohistochemistry. Here,
we show representative images of colon sections stained with anti-transforming growth factor
beta (TGF- ) antibodies. TGF- signalling has been demonstrated to be frequently
deregulated in human cancers, including colorectal cancer. While in normal or premalignant
cells it usually acts as a tumour suppressor, in advanced cancer it is frequently
overexpressed and the growth inhibitory function switch to an oncogenic one thus promoting
tumour cell proliferation and invasion.
Figure 9. AOM colon carcinogenesis model: colon length and specific weight.
Mutagenesis-induced colorectal cancer was induced in BALB/c mice by i.p. administration of
azoxymethane (AOM) at a dose of 5 mg/kg once a week for 6 weeks. Starting from day 1,
mice were randomized into 2 arms of 2 1 mice each which received treatment with 7 1D6 (at a
dose of 5 mg/kg) or vehicle only (PBS). Antibody was administered two times a week by i.p.
injection. An additional, third control arm contained 7 mice that received no AOM or antibody
and served as healthy control. Mice were sacrificed 8 weeks after the last AOM injection, i.e.
14 weeks after the experiment started. At autopsy, colons were collected and washed
through. Explanted colons were measured using a ruler and weighed. (A) Colon length. (B)
Colon specific weight.
Figure 10. AOM colon carcinogenesis model: tumour incidence and number.
Mutagenesis-induced colorectal cancer was induced in BALB/c mice as described in Figure 9
legend. Following measurements, colons were cut open longitudinally to expose tumour
masses. Tissues were stained ex vivo with a 1% Alcian Blue solution in order to highlight
tumour borders. Polips were counted using a stereo-microscope. (A) Tumour incidence. (B)
Mean tumour number.
Figure 11. AOM colon carcinogenesis model: representative images of colon
tumours. Representative images of the tumours quantified in Figure 10. Arrows indicate
macroscopically evident tumour masses. Magnification: 1X.
Figure 12. Intestinal (colorectal) inflammation model. Dextran sodium sulphate
(DSS) was added to the drinking water of Balb/c mice for 10 days. On day 10, DSS treatment
was interrupted and mice were put back on normal water. Starting from day 1, mice were
randomized into 7 arms which received treatment with 7 1G3, 7 1D6, 7 1G2 (at a dose of 1
mg/kg or 5 mg/kg) or vehicle only (PBS). An additional, eighth control arm received no DSS
or antibody and served as healthy control. Mice were sacrificed on day 12, i.e. 2 days after
DSS administration was interrupted. At autopsy, colons were collected, washed through, and
their length was determined using a ruler. Following measurement, colons were embedded in
paraffin and processed for histological analysis. During the whole course of the experiment,
mouse weight was monitored on a regular basis, and the clinical symptoms of ulcerative
colitis were assessed by determining faecal blood, rectal bleeding and stool consistency.
Each parameter was given a score from 0 (absence of the symptom) to 3 (maximal
manifestation of the symptom). Scores relative to the single parameters were summed
together to give rise to the DAI ranging from 0 to 9 . (A) Body weight over time (% relative to
time 0). (B) DAI over time. (C) Colon length at autopsy. Data of the 1 mg/kg arms and of the
5 mg/kg arms are shown in separate graphs for clarity.
Figure 13. Intestinal (colorectal) inflammation model. BALB/c mice were exposed
to dextran sodium sulphate (DSS) as described in Figure 12 legend. At autopsy, colons were
collected, measured, and then embedded in paraffin and processed for histological analysis.
Colon sections were stained with hematoxylin and eosin, examined by microscopy, and
photographed. Experimental arm, antibody dose and magnification are indicated close to
each image.
DETAILED DESCRIPTION
As used herein, the terms "MET protein" or "MET antigen" or "MET" are used
interchangeably and refer to the receptor tyrosine kinase that, in its wild-type form, binds
Hepatocyte Growth Factor (HGF). “MET” as used herein refers to human MET unless
otherwise specified. The terms “human MET protein” or “human MET receptor” or “human
MET” or “hMET” are used interchangeably to refer to human MET (GenBank accession
number: X54559), including the native human MET protein naturally expressed in the human
host and/or on the surface of human cultured cell lines, as well as recombinant forms and
fragments thereof and also naturally occurring mutant forms. The terms “mouse MET
protein” or “mouse MET receptor” or “mouse MET” or “mMET” are used interchangeably to
refer to mouse MET (GenBank accession number: NM 008591), including the native mouse
MET protein naturally expressed in the mouse host and/or on the surface of mouse cultured
cell lines, as well as recombinant forms and fragments thereof and also naturally occurring
mutant forms.
As used herein, “HGF-MET agonist” and “MET agonist” are used interchangeably to
refer to non-native agents that promote signalling via the MET protein - i.e. agents other than
HGF that bind MET and increase MET signalling. Agonist activity on binding of MET by MET
agonists is indicated by molecular and/or cellular responses that (at least partially) mimic the
molecular and cellular responses induced upon HGF-MET binding. Suitable methods for
measuring MET agonist activity are described herein, including the Examples. A “full agonist”
is a MET agonist that increases MET signalling in response to binding to an extent at least
similar, and optionally exceeding, the extent to which MET signalling increases in response
to binding of the native HGF ligand. Examples of the level of MET signalling induced by “full
agonists”, as measured by different methods of determining MET signalling, are provided
herein.
HGF-MET agonists may be small molecules, binding proteins such as antibodies or
antigen binding fragments, aptamers or fusion proteins. A particular example of a MET
agonist is an anti-MET agonist antibody.
As used herein, “treatment” or “treating” refers to effective therapy of the relevant
condition (cancer (e.g. colorectal cancer) or fibrosis) - that is, an improvement in the health
of the subject. Treatment may be therapeutic or prophylactic treatment - that is, therapeutic
treatment of subjects suffering from the condition, or prophylactic treatment of a subject so
as to reduce their risk of contracting the condition or the severity of the condition once
contracted. Therapeutic treatment may be characterised by improvement in the health of the
subject compared to prior to treatment. Therapeutic treatment may be characterised by
improvement in the health of the subject compared to a comparable control subject that has
not received treatment. Prophylactic treatment may be characterised by improvement in the
health of the subject compared to a control subject (or population of control subjects) that
has not been treated. Prophylactic treatment may also be characterised by prevention of the
deterioration of the health of the subject.
As used herein, the term "antibody" includes an immunoglobulin having a
combination of two heavy and two light chains which have significant specific immuno-
reactive activity to an antigen of interest (e.g. human MET). The terms “anti-MET antibodies”
or “MET antibodies” are used interchangeably herein to refer to antibodies which exhibit
immunological specificity for human MET protein. “Specificity” for human MET does not
exclude cross-reaction with species homologues of MET. In particular, “agomAbs” as used
herein refers MET antibodies that bind to both human MET and mouse MET.
“Antibody” as used herein encompasses antibodies of any human class (e.g. IgG,
IgM, IgA, IgD, IgE) as well as subclasses/isotypes thereof (e.g. lgG1 , lgG2, lgG3, lgG4,
lgA1 ) . Antibody as used herein also refers to modified antibodies. Modified antibodies
include synthetic forms of antibodies which are altered such that they are not naturally
occurring, e.g., antibodies that comprise at least two heavy chain portions but not two
complete heavy chains (such as, domain deleted antibodies or minibodies); multispecific
forms of antibodies (e.g., bispecific, trispecific, etc.) altered to bind to two or more different
antigens or to different epitopes on a single antigen); heavy chain molecules joined to scFv
molecules and the like. In addition, the term “modified antibody” includes multivalent forms of
antibodies (e.g., trivalent, tetravalent, etc., antibodies that bind to three or more copies of the
same antigen).
Antibodies described herein may possess antibody effector function, for example one
or more of antibody dependent cell-mediated cytotoxicity (ADCC), complement dependent
cytotoxicity (CDC) and antibody dependent cellular phagocytosis (ADCP). Alternatively, in
certain embodiments antibodies for use according to the invention have an Fc region that
has been modified such that one or more effector functions, for example all effector
functions, are abrogated.
Antibodies comprise light and heavy chains, with or without an interchain covalent
linkage between them. An antigen-binding fragment of an antibody includes peptide
fragments that exhibit specific immuno-reactive activity to the same antigen as the antibody
(e.g. MET). Examples of antigen-binding fragments include scFv fragments, Fab fragments,
and F(ab’)2 fragments.
As used herein, the terms "variable region" and "variable domain" are used
interchangeably and are intended to have equivalent meaning. The term "variable" refers to
the fact that certain portions of the variable domains VH and VL differ extensively in
sequence among antibodies and are used in the binding and specificity of each particular
antibody for its target antigen. However, the variability is not evenly distributed throughout
the variable domains of antibodies. It is concentrated in three segments called
"hypervariable loops" in each of the VL domain and the VH domain which form part of the
antigen binding site. The first, second and third hypervariable loops of the VLambda light
chain domain are referred to herein as L 1 (A), L2(A) and L3(A) and may be defined as
comprising residues 24-33 (L1 (A), consisting of 9 , 10 or 11 amino acid residues), 49-53
(L2(A), consisting of 3 residues) and 90-96 (L3(A), consisting of 5 residues) in the VL domain
(Morea et al., Methods 20, 267-279, 2000). The first, second and third hypervariable loops of
the VKappa light chain domain are referred to herein as L 1 (K), L2(K) and L3(K) and may be
defined as comprising residues 25-33 (L1 (K), consisting of 6 , 7 , 8 , 11, 12 or 13 residues), 49-
53 (L2(K), consisting of 3 residues) and 90-97 (L3(K), consisting of 6 residues) in the VL
domain (Morea et al., Methods 20, 267-279, 2000). The first, second and third hypervariable
loops of the VH domain are referred to herein as H 1 , H2 and H3 and may be defined as
comprising residues 25-33 (H1 , consisting of 7 , 8 or 9 residues), 52-56 (H2, consisting of 3 or
4 residues) and 9 1- 105 (H3, highly variable in length) in the VH domain (Morea et al.,
Methods 20, 267-279, 2000).
Unless otherwise indicated, the terms L 1 , L2 and L3 respectively refer to the first,
second and third hypervariable loops of a VL domain, and encompass hypervariable loops
obtained from both Vkappa and Vlambda isotypes. The terms H 1 , H2 and H3 respectively
refer to the first, second and third hypervariable loops of the VH domain, and encompass
hypervariable loops obtained from any of the known heavy chain isotypes, including , , ,
or .
The hypervariable loops L 1 , L2, L3, H 1 , H2 and H3 may each comprise part of a
"complementarity determining region" or "CDR", as defined below. The terms "hypervariable
loop" and "complementarity determining region" are not strictly synonymous, since the
hypervariable loops (HVs) are defined on the basis of structure, whereas complementarity
determining regions (CDRs) are defined based on sequence variability (Kabat et al.,
Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National
Institutes of Health, Bethesda, MD, 1991) and the limits of the HVs and the CDRs may be
different in some VH and VL domains.
The CDRs of the VL and VH domains can typically be defined as comprising the
following amino acids: residues 24-34 (CDRL1), 50-56 (CDRL2) and 89-97 (CDRL3) in the
light chain variable domain, and residues 31-35 or 3 1-35b (CDRH1), 50-65 (CDRH2) and 95-
102 (CDRH3) in the heavy chain variable domain; (Kabat et al., Sequences of Proteins of
Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health,
Bethesda, MD, 1991 ) . Thus, the HVs may be comprised within the corresponding CDRs and
references herein to the "hypervariable loops" of VH and VL domains should be interpreted
as also encompassing the corresponding CDRs, and vice versa, unless otherwise indicated.
The more highly conserved portions of variable domains are called the framework
region (FR), as defined below. The variable domains of native heavy and light chains each
comprise four FRs (FR1 , FR2, FR3 and FR4, respectively), largely adopting a -sheet
configuration, connected by the three hypervariable loops. The hypervariable loops in each
chain are held together in close proximity by the FRs and, with the hypervariable loops from
the other chain, contribute to the formation of the antigen-binding site of antibodies.
Structural analysis of antibodies revealed the relationship between the sequence and the
shape of the binding site formed by the complementarity determining regions (Chothia et al.,
J. Mol. Biol. 227, 799-817, 1992; Tramontane et al., J. Mol. Biol, 2 15 , 175-1 82, 1990).
Despite their high sequence variability, five of the six loops adopt just a small repertoire of
main-chain conformations, called “canonical structures”. These conformations are first of all
determined by the length of the loops and secondly by the presence of key residues at
certain positions in the loops and in the framework regions that determine the conformation
through their packing, hydrogen bonding or the ability to assume unusual main-chain
conformations.
As used herein, the term "CDR" or "complementarity determining region" means the
non-contiguous antigen combining sites found within the variable region of both heavy and
light chain polypeptides. These particular regions have been described by Kabat et al., J.
Biol. Chem. 252, 6609-661 6 , 1977, by Kabat et al., Sequences of Proteins of Immunological
Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD, 1991 , by
Chothia et al., J. Mol. Biol. 196, 901-91 7 , 1987, and by MacCallum et al., J. Mol. Biol. 262,
732-745, 1996, where the definitions include overlapping or subsets of amino acid residues
when compared against each other. The amino acid residues which encompass the CDRs
as defined by each of the above cited references are set forth for comparison. Preferably,
the term “CDR” is a CDR as defined by Kabat based on sequence comparisons.
Table 1: CDR definitions.
As used herein, the term “framework region” or “FR region” includes the amino acid
residues that are part of the variable region, but are not part of the CDRs (e.g., using the
Kabat definition of CDRs). Therefore, a variable region framework is between about 100-120
amino acids in length but includes only those amino acids outside of the CDRs. For the
specific example of a heavy chain variable domain and for the CDRs as defined by Kabat et
al., framework region 1 corresponds to the domain of the variable region encompassing
amino acids 1-30; framework region 2 corresponds to the domain of the variable region
encompassing amino acids 36-49; framework region 3 corresponds to the domain of the
variable region encompassing amino acids 66-94, and framework region 4 corresponds to
the domain of the variable region from amino acids 103 to the end of the variable region.
The framework regions for the light chain are similarly separated by each of the light claim
variable region CDRs. Similarly, using the definition of CDRs by Chothia et al. or McCallum
et al. the framework region boundaries are separated by the respective CDR termini as
described above. In preferred embodiments the CDRs are as defined by Kabat.
In naturally occurring antibodies, the six CDRs present on each monomeric antibody
are short, non-contiguous sequences of amino acids that are specifically positioned to form
the antigen binding site as the antibody assumes its three dimensional configuration in an
aqueous environment. The remainder of the heavy and light variable domains show less
inter-molecular variability in amino acid sequence and are termed the framework regions.
The framework regions largely adopt a -sheet conformation and the CDRs form loops which
connect, and in some cases form part of, the -sheet structure. Thus, these framework
regions act to form a scaffold that provides for positioning the six CDRs in correct orientation
by inter-chain, non-covalent interactions. The antigen binding site formed by the positioned
CDRs defines a surface complementary to the epitope on the immunoreactive antigen. This
complementary surface promotes the non-covalent binding of the antibody to the
immunoreactive antigen epitope. The position of CDRs can be readily identified by one of
ordinary skill in the art.
As used herein, the term “hinge region” includes the portion of a heavy chain
molecule that joins the CH1 domain to the CH2 domain. This hinge region comprises
approximately 25 residues and is flexible, thus allowing the two N-terminal antigen binding
regions to move independently. Hinge regions can be subdivided into three distinct domains:
upper, middle, and lower hinge domains (Roux et al., J. Immunol. 161 , 4083-4090, 1998).
MET antibodies comprising a “fully human” hinge region may contain one of the hinge region
sequences shown in Table 2 below.
Table 2 : Human hinge sequences.
As used herein the term “CH2 domain” includes the portion of a heavy chain molecule
that extends, e.g., from about residue 244 to residue 360 of an antibody using conventional
numbering schemes (residues 244 to 360, Kabat numbering system; and residues 231 -340,
EU numbering system; Kabat et al., Sequences of Proteins of Immunological Interest, 5th
Ed. Public Health Service, National Institutes of Health, Bethesda, MD ( 1991). The CH2
domain is unique in that it is not closely paired with another domain. Rather, two N-linked
branched carbohydrate chains are interposed between the two CH2 domains of an intact
native IgG molecule. It is also well documented that the CH3 domain extends from the CH2
domain to the C-terminal of the IgG molecule and comprises approximately 108 residues.
As used herein, the term “fragment” refers to a part or portion of an antibody or
antibody chain comprising fewer amino acid residues than an intact or complete antibody or
antibody chain. The term “antigen-binding fragment” refers to a polypeptide fragment of an
immunoglobulin or antibody that binds antigen or competes with intact antibody (i.e., with the
intact antibody from which they were derived) for antigen binding (i.e., specific binding to
MET). As used herein, the term “fragment” of an antibody molecule includes antigen-binding
fragments of antibodies, for example, an antibody light chain variable domain (VL), an
antibody heavy chain variable domain (VH), a single chain antibody (scFv), a F(ab’)2
fragment, a Fab fragment, an Fd fragment, an Fv fragment, and a single domain antibody
fragment (DAb). Fragments can be obtained, e.g., via chemical or enzymatic treatment of an
intact or complete antibody or antibody chain or by recombinant means.
As used herein, “subject” and “patient” are used interchangeably to refer to a human
individual.
Method of treating cancer
Effective treatment of cancer with an HGF-MET agonist has not been previously
demonstrated.
It is surprisingly demonstrated herein that administration of an HGF-MET agonist (i.e.
an agonist of MET that is not HGF) effectively treats cancer in two models. In particular, the
MET agonist treated colorectal cancer in a mutagenesis model, where mice with genetic
mutations were treated such that the tumour incidence and number of tumours was reduced
compared to untreated controls, and also, further advantageously, compared to
administration of the native MET ligand (HGF). Furthermore, administration of a MET agonist
also prevented development of tumours in a model of intestinal (colorectal) inflammation-
induced tumour formation. Notably, a MET antagonist agent failed to treat cancer in either
model.
Accordingly, in a first aspect there is provided a method of treating cancer comprising
administering to a subject in need thereof an HGF-MET agonist. Also provided is an HGF-
Met agonist (e.g. a MET agonist antibody) for use in treating cancer, or for the manufacture
of a medicament for treating cancer.
Cancers particularly suitable to be treated according to the methods described herein
include cancers of epithelial origin. Cancers particularly suitable to be treated according to
the claimed methods are gastrointestinal cancers, for example: oesophageal cancer,
stomach cancer, pancreatic cancer, liver cancer, gallbladder cancer, colorectal cancer and
anal cancer.
Cancers associated with chronic inflammation are also particularly suited to being
treated according to the provided methods. For example, liver cancer is associated with
inflammation caused by hepatitis virus infection, stomach cancer is associated with
inflammation caused by Helicobacter pylori infection, and colorectal cancer is associated with
intestinal inflammation. Accordingly, in certain embodiments, the method is a method of
treating a cancer associated with chronic inflammation. In certain embodiments, the method
is a method of treating liver cancer. In certain embodiments, the method is a method of
treating stomach cancer.
As demonstrated herein, HGF-MET agonists are particularly effective at treating
colorectal cancer. Therefore, in a preferred embodiment of the methods described herein,
the method is a method of treating colorectal cancer. Also provided is an HGF-Met agonist
(e.g. a MET agonist antibody) for use in treating colorectal cancer, or for the manufacture of
a medicament for treating colorectal cancer.
Treatment of cancer, such as colorectal cancer, can be therapeutic or prophylactic
treatment - that is, therapeutic treatment of subjects suffering from the condition, or
prophylactic treatment of a subject so as to reduce their risk of contracting the condition or
the severity of the condition once contracted. Therefore, in certain embodiments, treatment
of cancer (such as colorectal cancer) is therapeutic. In certain embodiments, therapeutic
treatment can be characterised by a decrease in the number of tumours or cancerous polyps
in a subject that has been administered a MET agonist compared to before administration of
the MET agonist. In certain embodiments, treatment of cancer (such as colorectal cancer)
can be characterised by a decrease in the size or volume of tumours or cancerous polyps
compared to before administration of the MET agonist. In certain embodiments, treatment
can be characterised by decrease in the number, size and/or volume of tumours or
cancerous polyps in the subject compared to a control subject that has not been
administered a MET agonist.
In further embodiments of methods for treatment of colorectal cancer, therapeutic
treatment may be further characterised by a decrease in the extent of colon fibrosis in the
subject compared to before administration of the MET agonist. Means for determining the
extent of fibrosis would be familiar to the skilled person and include, for example, determining
the extent of collagen deposition in a representative biopsy.
In certain embodiments, treatment of cancer, for example colorectal cancer, may be
prophylactic treatment. In certain embodiments, prophylactic treatment may be characterized
by a decrease in the number of tumours or cancerous polyps in a subject (or population of
subjects) that has been administered a Met agonist compared to a control subject (or
population of control subjects) that has not been administered a MET agonist. In certain
embodiments, prophylactic treatment of cancer, for example colorectal cancer, can be
characterized by a decrease in the size or volume of tumours or cancerous polyps in a
subject (or population of subjects) that has been administered a Met agonist compared to a
control subject (or population of control subjects) that has not received a MET agonist.
In further embodiments, prophylactic treatment of colorectal cancer can be further
characterised by a decrease in the extent of colon fibrosis in a subject (or population of
subjects) that has been administered a MET agonist compared to a control subject (or
population of control subjects) that has not been administered a MET agonist. Means for
determining the extent of fibrosis would be familiar to the skilled person and include, for
example, determining the extent of collagen deposition in a representative biopsy.
As will be appreciated by the skilled person, a “control subject” as used herein refers
to a subject of comparable disease state to the subject being administered the HGF-MET
agonist.
Method of treating colorectal fibrosis
It is further surprisingly demonstrated herein that administration of an HGF-MET
agonist (i.e. an agonist of MET that is not HGF) effectively treats colorectal fibrosis. A subject
is particularly susceptible to colorectal fibrosis when suffering from intestinal inflammation.
Accordingly, in a further aspect is provided a method of treating colorectal fibrosis,
comprising administering to a subject an HGF-MET agonist. Means for determining the
extent of fibrosis in a subject would be familiar to the skilled person and include, for example,
determining the extent of collagen deposition in a representative biopsy. The use of an HGF-
MET agonist for use for treating colorectal fibrosis, or for the manufacture of a medicament
for treating colorectal fibrosis, is also provided.
In certain embodiments of methods for treatment of colorectal fibrosis, treatment may
be therapeutic treatment. In certain embodiments, therapeutic treatment can be
characterised by a decrease in the extent of colon fibrosis in the subject compared to before
administration of the MET agonist. In certain embodiments, therapeutic treatment can be
characterised by a decrease in the extent of colon fibrosis in the subject compared to a
control subject that has not been administered a MET agonist.
In certain embodiments, treatment of colorectal cancer can be prophylactic treatment.
In certain embodiments, prophylactic treatment may be characterised by a decrease in the
extent of colon fibrosis in a subject (or population of subjects) that has been administered a
MET agonist compared to a control subject (or population of control subjects) that has not
been administered a MET agonist.
As will be appreciated by the skilled person, a “control subject” as used herein refers
to a subject of comparable disease state to the subject being administered the HGF-MET
agonist.
Subject or Patient
As surprisingly demonstrated herein, administration of an HGF-MET agonist
effectively treats cancer in a subject. It is further demonstrated that HGF-MET agonists are
particularly effective at treating colorectal cancer, especially in patients predisposed or at risk
of developing colorectal cancer.
Patients at increased risk of colorectal cancer are those who are more likely to
develop colorectal cancer compared to an otherwise comparable healthy individual. Factors
known to increase risk for colorectal cancer include, for example, age of >65 years, male
gender, smoking, obesity, increased alcohol intake, increased red or processed meat intake.
Methods described herein for treating colorectal cancer will be particularly effective at
treating subjects having one or more of these risk factors.
Accordingly, in certain embodiments is provided a method of treating colorectal
cancer comprising administering to a subject in need thereof an HGF-MET agonist, wherein
the subject has been identified as at increased risk of colorectal cancer. In certain such
embodiments, the subject has one or more risk factors selected from the group consisting of:
age of >65 years, male gender, smoking, obesity, increased alcohol intake, increased red or
processed meat intake.
Certain genetic conditions are also known risk factors for developing colorectal
cancer. For example, hereditary nonpolyposis colorectal cancer (HNPCC or Lynch
syndrome), Gardner syndrome, and familial adenomatous polyposis (FAP) are syndromes
known to increase risk of a subject developing colorectal cancer. Accordingly, in certain
embodiments, the subject has a predisposition to developing colorectal cancer. In certain
such embodiments, the subject has FAP, HNPCC or Gardner syndrome.
A significant risk factor for colorectal cancer and also for colorectal fibrosis is
intestinal inflammation, in particular colorectal inflammation. Identifying subjects with
colorectal inflammation would be within the ability of the skilled person. For example,
colorectal inflammation can be identified visually via endoscope, histologically via biopsy, or
by measuring a marker of colorectal inflammation such as faecal calprotectin. Colorectal
inflammation is characteristic of patients suffering from inflammatory bowel disease, for
example Crohn’s Disease or ulcerative colitis.
As demonstrated in the Examples, methods described herein are particularly effective
in subjects with colorectal inflammation. In a model of gut inflammation, a HGF-MET agonist
effectively reduced both tumour burden and colorectal fibrosis.
Accordingly, in embodiments of all aspects of the claimed methods, the subject has
been diagnosed with colorectal inflammation prior to administration of the HGF-MET agonist.
In certain embodiments, the subject has inflammatory bowel disease (IBD), for example
Crohn’s Disease or ulcerative colitis.
Administration
It will be appreciated that, as used herein, administration of an HGF-MET agonist (for
example an anti-MET agonist antibody) to a subject refers to administration of an effective
amount of the agonist.
In certain embodiments, the HGF-MET agonist is administered at a dose in the range
of from about 0.1 mg/kg to about 10 mg/kg per dose. In certain embodiments, the HGF-MET
agonist is administered at a dose in the range of from 0.5 mg/kg to about 10 mg/kg. That is, a
dose of about 0.5, 1, 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 or 10 mg/kg. In certain preferred embodiments, the
HGF-MET agonist is administered at a dose in the range of from about 1 mg/kg to about
5mg/kg. In certain preferred embodiments, the HGF-MET agonist is administered at a dose
of 1 mg/kg or 5 mg/kg.
Suitable routes for administration of the HGF-MET agonist (for example an anti-MET
agonist antibody) to a subject would be familiar to the skilled person. Preferably the MET
agonist is administered parenterally. In certain preferred embodiments, the HGF-MET
agonist is administered per os (p.o.), subcutaneously (s.c.), intravenously (i.v.), intradermally
(i.d.), intramuscularly (i.m.) or intraperitoneally (i.p.). In certain preferred embodiments, the
HGF-MET agonist is a MET agonist antibody and is administered intravenously.
The HGF-MET agonist (for example anti-MET agonist antibody) can be administered
according to a regimen that maintains an effective level of the agonist in the subject. The
skilled person is familiar with suitable dosage regimens. For example, in certain
embodiments, the HGF-MET agonist (e.g. MET agonist antibody) is administered according
to a dosage regimen of at least once per week - that is, a dose is administered
approximately every 7 days or more frequently. In certain embodiments, the HGF-MET
agonist (e.g. MET agonist antibody) is administered 1-3 times a week (i.e. 1, 2 or 3 times a
week). In certain preferred embodiments, the HGF-MET agonist (e.g. MET agonist antibody)
is administered twice per week. In certain preferred embodiments, the HGF-MET agonist is a
MET agonist antibody and is administered once per week or twice per week.
For the methods described herein, the HGF-MET agonist (e.g. MET agonist antibody)
is administered for a period sufficient to achieve effective treatment. The skilled person is
able to determine the necessary treatment period for any individual patient. In certain
embodiments, the HGF-MET agonist (e.g. a MET agonist antibody) is administered for a
treatment period of at least 1 week. In certain embodiments, the HGF-MET agonist (e.g. a
MET agonist antibody) is administered for a treatment period of at least 2 weeks, at least 3
weeks, or at least 4 weeks. In certain embodiments, the HGF-MET agonist (e.g. a MET
agonist antibody) is administered for a treatment period of at least 1 month, at least 2 months
or at least 3 months. In certain preferred embodiments, the HGF-MET agonist is a MET
agonist antibody and is administered for a treatment period of 3 months.
It will be appreciated that the HGF-MET agonist (e.g. a MET agonist antibody) may
be administered according to any combination of the described doses, dosage regimens and
treatment periods. For example, in certain embodiments, the HGF-MET agonist (e.g. a MET
agonist antibody) may be administered according to a dosage regimen of twice per week, at
a dose of from 1mg/kg to 5 mg/kg, for a period of at least 3 months. Other embodiments of
the methods explicitly include other combinations of the recited doses, dosage regimens and
treatment periods.
HGF-MET agonist
It is demonstrated in the Examples below that an HGF-Met agonist effectively treats
cancer, in particular colorectal cancer. It is also demonstrated that an HGF-Met agonist
effectively treats colorectal fibrosis. Therefore, in all aspects of the invention, an HGF-MET
agonist is to be administered to a subject or patient to treat the indicated condition (i.e.
cancer (e.g. colorectal cancer) or colorectal fibrosis). “HGF-MET agonist” and “MET agonist”
are used interchangeably to refer to non-native agents that promote signalling via the MET
protein - i.e. agents other than HGF that bind MET and increase MET signalling. Such
agents may be small molecules, binding proteins such as antibodies or antigen binding
fragments, aptamers or fusion proteins. A particular example of a MET agonist is an anti-
MET agonist antibody.
Agonist activity on binding of MET by the MET agonists described herein is indicated
by molecular and/or cellular responses that (at least partially) mimic the molecular and
cellular responses induced upon HGF-MET binding.
Methods for determining MET agonism according to the invention, for example by
MET agonist antibodies and antigen binding fragments, would be familiar to the skilled
person. For example, MET agonism may be indicated by molecular responses such as
phosphorylation of the MET receptor and/or cellular responses, for example those detectable
in a cell scattering assay, an anti-apoptosis assay and/or a branching morphogenesis assay.
MET agonism may be determined by the level of phosphorylation of the MET receptor
upon binding. In this context, a MET agonist antibody or antigen binding fragment, for
example, causes auto-phosphorylation of MET in the absence of receptor-ligand binding -
that is, binding of the antibody or antigen binding fragment to MET results in phosphorylation
of MET in the absence of HGF. Phosphorylation of MET may be determined by assays
known in the art, for example Western Blotting or phospho-MET ELISA (as described in
Basilico etal., J Clin Invest. 124, 3172-31 86, 2014, incorporated herein by reference).
MET agonism may alternatively be measured by induction of HGF-like cellular
responses. MET agonism can be measured using assays such as a cell scattering assay, an
anti-apoptosis assay and/or a branching morphogenesis assay. In this context, a MET
agonist, for example an antibody or antigen binding fragment, induces a response in cellular
assays such as these that resembles (at least partially) the response observed following
exposure to HGF.
For example, a MET agonist (for example a MET agonist antibody) may increase cell
scattering in response to the antibody compared to cells exposed to a control antibody (e.g.
lgG1).
By way of further example, a MET agonist (for example a MET agonist antibody) may
exhibit a protective potency against drug-induced apoptosis with an EC
50
of less than 32 nM.
By way of further example, a MET agonist (for example a MET agonist antibody) may exhibit
an E
max
cellular viability of greater than 20% compared to untreated cells.
By way of further example, a MET agonist (for example a MET agonist antibody) may
increase the number of branches per spheroid in cell spheroid preparations exposed to the
antibody or antigen binding fragment.
It is preferred that the MET agonists used according to the invention promote MET
signalling to a magnitude of at least 70% of the natural ligand, HGF - that is, that the
agonists are “full agonists”. In certain embodiments, the MET agonists promote signalling to
a magnitude of at least 80%, optionally at least 85%, at least 90%, at least 95% or at least
96%, at least 97%, at least 98%, at least 99% or at least 100% of HGF.
In certain embodiments, if MET agonism is determined using a phosphorylation
assay, the MET agonist, e.g. a MET antibody, exhibits a potency for MET with an EC
50
of
< 1nM. In certain embodiments, the MET agonist, e.g. a MET antibody, exhibits a potency for
MET agonism of an E
MAX
of at least 80% (as a percentage of maximal HGF-induced
activation).
In certain embodiments, if MET agonism is measured in a cell scattering assay, the
MET agonist, for example a MET antibody or antigen binding fragment, induces an increase
in cell scattering at least equivalent to 0.1 nM homologous HGF when the antibody
concentration is 0.1-1 nM.
In certain embodiments, if MET agonism is measured in an anti-apoptosis assay, the
MET agonist (for example a MET antibody or fragment thereof) exhibits an EC50 no more
than 1. 1x that of HGF. In certain embodiments, if MET agonism is measured in an ant i
apoptosis assay, the MET agonist (for example a MET antibody or fragment thereof) exhibits
an Emax cellular viability of greater than 90% that observed for HGF.
In certain embodiments, if MET agonism is measured in a branching morphogenesis
assay, cells treated with the MET agonist (e.g. a MET antibody or antigen binding fragment)
exhibit greater than 90% of the number of branches per spheroid induced by the same (non
zero) concentration of HGF.
HGF-MET agonists particularly preferred in all aspects of the invention are anti-MET
agonist antibodies, also referred to herein as “MET agonist antibodies”, “agonist antibodies”
and grammatical variations thereof. In other words, MET agonist antibodies (or antigen
binding fragments thereof) for use according to the invention bind MET and promote cellular
signalling via MET.
As demonstrated in the Examples, 7 1D6 is a MET agonist antibody that effectively
treats cancer (in particular colorectal cancer) and also colorectal fibrosis. 7 1D6 binds an
epitope on the SEMA domain of MET, in particular an epitope on blade 4-5 of the SEMA -
propeller. MET agonists binding an epitope on the SEMA domain of MET, in particular blade
4-5 of the SEMA -propeller have therefore been demonstrated to lead to effective treatment
of (colorectal) cancer. Antibody 7 1G2 has similar effects to 7 1D6 and also binds the SEMA
domain of MET, in particular blade 4-5 of the SEMA -propeller.
Thus, in certain embodiments is provided a method of treating cancer (for example
colorectal cancer), or a method of treating colorectal fibrosis, comprising administering a
MET agonist antibody or antigen binding fragment thereof, wherein the antibody or antigen
binding fragment binds an epitope in the SEMA domain of MET. In certain preferred
embodiments, the antibodies or fragments thereof binds an epitope located on a blade of the
SEMA -propeller. In certain embodiments, the epitope is located on blade 4 or 5 of SEMA -
propeller. In certain preferred embodiments, the antibody or antigen binding fragment binds
an epitope located between amino acids 314-372 of MET.
As shown in the Examples, MET agonist antibodies binding the SEMA domain of
MET, including 7 1D6 and 71G2, have been shown to bind to an epitope on MET that
includes residue Ile367 and residue Asp371 . Mutation at either of these residues impairs
binding of the antibodies to MET, with mutation of both residues completely abrogating
binding.
Therefore, in certain preferred embodiments is provided a method of treating cancer
(e.g. colorectal cancer), or a method of treating colorectal fibrosis, comprising administering
a MET agonist antibody or antigen binding fragment thereof, wherein the antibody or antigen
binding fragment recognises an epitope comprising the amino acid residue Ile367. In certain
preferred embodiments is provided a method of treating cancer (e.g. colorectal cancer), or a
method of treating colorectal fibrosis, comprising administering a MET agonist antibody or
antigen binding fragment thereof, wherein the antibody or antigen binding fragment
recognises an epitope comprising the amino acid residueAsp371 .
In certain preferred embodiments, the antibody or antigen binding fragment binds an
epitope comprising the amino acid residues Ile367 and Asp372 of MET.
As well as MET agonist antibodies binding the SEMA domain, also described herein
are agonist antibodies binding other MET domains. For example, 7 1G3 binds an epitope on
the PSI domain of MET. As demonstrated in the Examples, antibody 7 1G3 exhibits similar
potency to 7 1D6 for reducing intestinal inflammation. 7 1G3 will therefore also be effective at
treating colorectal cancer in a manner similar to 7 1D6. Similarly, 71G3 will also be effective
at treating colorectal fibrosis in a manner similar to 7 1D6.
Thus, in certain embodiments is provided a method of treating cancer (for example
colorectal cancer), or a method of treating colorectal fibrosis, comprising administering a
MET agonist antibody or antigen binding fragment thereof, wherein the antibody or antigen
binding fragment binds an epitope in the PSI domain of MET. In certain preferred
embodiments, the antibody or antigen binding fragment binds an epitope located between
amino acids 546 and 562 of MET.
As shown in the Examples, MET agonist antibodies binding the PSI domain of MET,
including 7 1G3, have been shown to bind to an epitope on MET that includes residue
Thr555. Mutation at this residue completely abrogated binding of the PSI-binding agonist
antibodies to MET.
Therefore, in certain preferred embodiments is provided a method of treating cancer
(e.g. colorectal cancer), or a method of treating colorectal fibrosis, comprising administering
a MET agonist antibody or antigen binding fragment thereof, wherein the antibody or antigen
binding fragment recognises an epitope comprising the amino acid residue Thr555.
Examples of MET agonist antibodies particularly suitable for use in treating cancer
(for example colorectal cancer), or for use in treating colorectal fibrosis, are those having a
combination of CDRs corresponding to the CDRs of an anti-MET antibody described herein.
Therefore, in certain embodiments, the antibody or antigen binding fragment comprises a
combination of VH and VL CDR sequences corresponding to a combination of VH CDRs
from a MET agonist antibody described in Table 3 and the corresponding combination of VL
CDRs for the same antibody in Table 4 .
In certain such embodiments, the antibody or antigen binding fragment comprises a
combination of CDRs corresponding to a combination of VH CDRs from a MET agonist
antibody described in Table 3 and the corresponding combination of VL CDRs for the same
antibody in Table 4 , and further having VH and VL domains with at least 90%, optionally at
least 95%, optionally at least 99%, preferably 100% sequence identity with the corresponding
VH and VL sequences of the antibody described in Table 6 . By way of clarification, in such
embodiments the permitted variation in percentage identity of the VH and VL domain
sequences is not in the CDR regions.
As demonstrated in the Examples, 7 1D6 is a MET agonist antibody that is a “full
agonist” of MET. That is, on binding of 7 1D6 to MET, the signalling response is similar to or
even exceeds the response to binding of the native HGF ligand. 7 1 D6 is demonstrated to
effectively treat (colorectal) cancer. Therefore in certain preferred embodiments is provided a
method of treating cancer (e.g. colorectal cancer) comprising administering an HGF-MET
agonist that is a full agonist - that is, an agonist that upon binding promotes MET signalling
to an extent of at least 70% of MET signalling upon HGF binding. Examples for measuring
MET agonism and examples of the effects of full agonists have already been described
herein.
Examples of MET full agonists, such as anti-MET antibodies that are full agonists
include 7 1D6 and 7 1G2, as demonstrated in the Examples. Therefore in particularly
preferred embodiments is provided a method of treating cancer (e.g. colorectal cancer), or a
method of treating colorectal fibrosis, comprising administering a MET agonist antibody or
antigen binding fragment thereof that is a full agonist of MET. In preferred such
embodiments, the antibody or fragment comprises a combination of CDRs having the
corresponding CDR sequences of antibody 7 1D6 (SEQ ID Nos: 30, 32, 34, 107, 109, and
111) , of antibody 7 1G2 (SEQ ID NOs: 44, 46, 48, 12 1 , 123, and 125), or of antibody 7 1G3
(SEQ ID Nos: 9 , 11, 13, 86, 88, and 90).
In preferred embodiments of all aspects, the MET agonist is a MET agonist antibody
or antigen binding fragment thereof having HCDR1 of [71 D6] SEQ ID NO: 30, HCDR2 of
SEQ ID NO: 32, HCDR3 of SEQ ID NO: 34, LCDR1 of SEQ ID NO: 107, LCDR2 of SEQ ID
NO: 109, and LCDR3 of SEQ ID NO: 111. In preferred such embodiments, the antibody or
antigen binding fragment comprises: a VH domain comprising SEQ ID NO: 163 or a
sequence at least 90% identical thereto, optionally at least 95%, at least 98% or at least 99%
identical thereto; and a VL domain comprising SEQ ID NO: 164 or a sequence at least 95%
thereto optionally at least 98% or at least 99% identical thereto. By way of clarification, in
such embodiments the permitted variation in percentage identity of the VH and VL domain
sequences is not in the CDR regions.
MET agonist antibodies for use as described herein can take various different
embodiments in which both a VH domain and a VL domain are present. The term "antibody"
herein is used in the broadest sense and encompasses, but is not limited to, monoclonal
antibodies (including full length monoclonal antibodies), polyclonal antibodies, multispecific
antibodies (e.g., bispecific antibodies), so long as they exhibit the appropriate immunological
specificity for a human MET protein and for a mouse MET protein. The term "monoclonal
antibody" as used herein refers to an antibody obtained from a population of substantially
homogeneous antibodies, i.e., the individual antibodies comprising the population are
identical except for possible naturally occurring mutations that may be present in minor
amounts. Monoclonal antibodies are highly specific, being directed against a single antigenic
site. Furthermore, in contrast to conventional (polyclonal) antibody preparations which
typically include different antibodies directed against different determinants (epitopes) on the
antigen, each monoclonal antibody is directed against a single determinant or epitope on the
antigen.
"Antibody fragments" comprise a portion of a full length antibody, generally the
antigen binding or variable domain thereof. Examples of antibody fragments include Fab,
Fab', F(ab')2, bi-specific Fab’s, and Fv fragments, diabodies, linear antibodies, single-chain
antibody molecules, a single chain variable fragment (scFv) and multispecific antibodies
formed from antibody fragments (see Holliger and Hudson, Nature Biotechnol. 23:1 126-
1136, 2005, the contents of which are incorporated herein by reference).
In preferred embodiments of all aspects provided herein, the MET agonist antibody or
antigen-binding fragment thereof is bivalent.
In non-limiting embodiments, the MET antibodies provided herein may comprise CH1
domains and/or CL domains, the amino acid sequence of which is fully or substantially
human. Therefore, one or more or any combination of the CH1 domain, hinge region, CH2
domain, CH3 domain and CL domain (and CH4 domain if present) may be fully or
substantially human with respect to its amino acid sequence. Such antibodies may be of any
human isotype, for example lgG1 or lgG4.
Advantageously, the CH1 domain, hinge region, CH2 domain, CH3 domain and CL
domain (and CH4 domain if present) may all have fully or substantially human amino acid
sequence. In the context of the constant region of a humanised or chimeric antibody, or an
antibody fragment, the term "substantially human" refers to an amino acid sequence identity
of at least 90%, or at least 92%, or at least 95%, or at least 97%, or at least 99% with a
human constant region. The term “human amino acid sequence” in this context refers to an
amino acid sequence which is encoded by a human immunoglobulin gene, which includes
germline, rearranged and somatically mutated genes. Such antibodies may be of any human
isotype, with human lgG4 and lgG1 being particularly preferred.
MET agonist antibodies may also comprise constant domains of “human” sequence
which have been altered, by one or more amino acid additions, deletions or substitutions with
respect to the human sequence, excepting those embodiments where the presence of a
“fully human” hinge region is expressly required. The presence of a “fully human” hinge
region in the MET antibodies of the invention may be beneficial both to minimise
immunogenicity and to optimise stability of the antibody.
The MET agonist antibodies may be of any isotype, for example IgA, IgD, IgE IgG, or
IgM. In preferred embodiments, the antibodies are of the IgG type, for example lgG1 , lgG2a
and b, lgG3 or lgG4. lgG1 and lgG4 are particularly preferred. Within each of these sub
classes it is permitted to make one or more amino acid substitutions, insertions or deletions
within the Fc portion, or to make other structural modifications, for example to enhance or
reduce Fc-dependent functionalities.
In non-limiting embodiments, it is contemplated that one or more amino acid
substitutions, insertions or deletions may be made within the constant region of the heavy
and/or the light chain, particularly within the Fc region. Amino acid substitutions may result in
replacement of the substituted amino acid with a different naturally occurring amino acid, or
with a non-natural or modified amino acid. Other structural modifications are also permitted,
such as for example changes in glycosylation pattern (e.g. by addition or deletion of N- or O-
linked glycosylation sites). Depending on the intended use of the MET antibody, it may be
desirable to modify the antibody of the invention with respect to its binding properties to Fc
receptors, for example to modulate effector function.
In certain embodiments, the MET antibodies may comprise an Fc region of a given
antibody isotype, for example human lgG1 , which is modified in order to reduce or
substantially eliminate one or more antibody effector functions naturally associated with that
antibody isotype. In non-limiting embodiments, the MET antibody may be substantially
devoid of any antibody effector functions. In this context, “antibody effector functions”
include one or more or all of antibody-dependent cellular cytotoxicity (ADCC), complement-
dependent cytotoxicity (CDC) and antibody-dependent cellular phagocytosis (ADCP).
The amino acid sequence of the Fc portion of the MET antibody may contain one or
more mutations, such as amino acid substitutions, deletions or insertions, which have the
effect of reducing one or more antibody effector functions (in comparison to a wild type
counterpart antibody not having said mutation). Several such mutations are known in the art
of antibody engineering. Non-limiting examples, suitable for inclusion in the MET antibodies
described herein, include the following mutations in the Fc domain of human lgG4 or human
lgG1 : N297A, N297Q, LALA (L234A, L235A), AAA (L234A, L235A, G237A) or D265A (amino
acid residues numbering according to the EU numbering system in human lgG1).
In certain embodiments of all aspects of the invention, therefore, the anti-MET agonist
antibody is an agonist antibody of both human MET and mouse MET.
Pharmaceutical compositions
Also provided in accordance with the invention are pharmaceutical compositions for
use in the methods described herein. Therefore in a further aspect of the invention is
provided a pharmaceutical composition comprising an HGF-MET agonist, for example an
anti-MET agonist antibody, and a pharmaceutically acceptable excipient or carrier for use in
a method according to the invention. Suitable pharmaceutically acceptable carriers and
excipients would be familiar to the skilled person. Examples of pharmaceutically acceptable
carriers and excipients suitable for inclusion in pharmaceutical compositions of the invention
include sodium citrate, glycine, polysorbate (e.g. polysorbate 80) and saline solution.
In certain embodiments, the MET agonist, for example anti-MET agonist antibody, is
administered to the subject parenterally, preferably intravenously (i.v.). In certain
embodiments the MET agonist, for example anti-MET agonist antibody, is administered as a
continuous i.v. infusion until the desired dose is achieved. In certain embodiments the MET
agonist, for example anti-MET agonist antibody, is administered orally (per os).
EXAMPLES
The invention will be further understood with reference to the following non-limiting
experimental examples.
Example 1: Generation of ant-MET agonist antibodies - Immunization of llamas
Immunizations of llamas and harvesting of peripheral blood lymphocytes (PBLs) as
well as the subsequent extraction of RNA and amplification of antibody fragments were
performed as described (De Haard et al., J. Bact. 187:4531-4541 , 2005). Two adult llamas
(Lama glama) were immunized by intramuscular injection of a chimeric protein consisting of
the extracellular domain (ECD) of human MET fused to the Fc portion of human lgG1 (MET-
Fc; R&D Systems). Each llama received one injection per week for six weeks, for a total of
six injections. Each injection consisted in 0.2 mg protein in Freund’s Incomplete Adjuvant in
the neck divided over two spots.
Blood samples of 10 ml were collected pre- and post-immunization to investigate the
immune response. Approximately one week after the last immunization, 400 ml of blood was
collected and PBLs were obtained using the Ficoll-Paque method. Total RNA was extracted
by the phenol-guanidine thiocyanate method (Chomczynski et al., Anal. Biochem. 162:1 56-
159, 1987) and used as template for random cDNA synthesis using the SuperScriptTM III
First-Strand Synthesis System kit (Life Technologies). Amplification of the cDNAs encoding
the VH-CH1 regions of llama lgG1 and VL-CL domains ( κ and λ) and subcloning into the
phagemid vector pCB3 was performed as described (de Haard et al., J Biol Chem.
274:1821 8-18230, 1999). The E. coli strain TG1 (Netherland Culture Collection of Bacteria)
was transformed using recombinant phagemids to generate 4 different Fab-expressing
phage libraries (one and one library per immunized llama). Diversity was in the range of
108- 10 9 .
The immune response to the antigen was investigated by ELISA. To this end, we
obtained the ECDs of human MET (UniProtKB # P08581 ; aa 1-932) and of mouse MET
(UniProtKB # P 16056.1 ; aa 1-931) by standard protein engineering techniques. Human or
mouse MET ECD recombinant protein was immobilized in solid phase (100 ng/well in a 96-
well plate) and exposed to serial dilutions of sera from llamas before (day 0) or after (day 45)
immunization. Binding was revealed using a mouse anti-llama lgG1 (Daley et al., Clin.
Vaccine Immunol. 12, 2005) and a HRP-conjugated donkey anti-mouse antibody (Jackson
Laboratories). Both llamas displayed an immune response against human MET ECD.
Consistent with the notion that the extracellular portion of human MET displays 87%
homology with its mouse orthologue, a fairly good extent of cross-reactivity was also
observed with mouse MET ECD.
Example 2 : Selections and screenings of Fabs binding to both human and mouse
MET
Fab-expressing phages from the libraries described above were produced according
to standard phage display protocols. For selection, phages were first adsorbed to
immobilized recombinant human MET ECD, washed, and then eluted using trypsin. After two
cycles of selection with human MET ECD, two other cycles were performed in the same
fashion using mouse MET ECD. In parallel, we also selected phages alternating a human
MET ECD cycle with a mouse MET ECD cycle, for a total of four cycles. Phages selected by
the two approaches were pooled together and then used to infect TG1 E. coli. Individual
colonies were isolated and secretion of Fabs was induced using IPTG (Fermentas). The Fab-
containing periplasmic fraction of bacteria was collected and tested for its ability to bind
human and mouse MET ECD by Surface Plasmon Resonance (SPR). Human or mouse
MET ECD was immobilized on a CM-5 chip using amine coupling in sodium acetate buffer
(GE Healthcare). The Fab-containing periplasmic extracts were loaded into a BIACORE
3000 apparatus (GE Healthcare) with a flow rate of 30 /min. The Fab off-rates (k
off
) were
measured over a two minute period. Binding of Fabs to human and mouse MET was further
characterized by ELISA using MET ECD in solid phase and periplasmic crude extract in
solution. Because Fabs are engineered with a MYC flag, binding was revealed using HRP-
conjugated anti-MYC antibodies (ImTec Diagnostics).
Fabs that bound to both human and mouse MET in both SPR and ELISA were
selected and their corresponding phages were sequenced (LGC Genomics). Cross-reactive
Fab sequences were divided into families based on VH CDR3 sequence length and content.
VH families were given an internal number not based on IMTG (International
Immunogenetics Information System) nomenclature. Altogether, we could identify 11
different human/mouse cross-reactive Fabs belonging to 8 VH families. The CDR and FR
sequences of heavy chain variable regions are shown in Table 3 . The CDR and FR
sequences of light chain variable regions are shown in Table 4 . The full amino acid
sequences of heavy chain and light chain variable regions are shown in Table 5 . The full







































































































































































































































The various Fab families and their ability to bind human and mouse MET are
shown in Table 7 .
Table 7 : Fabs binding to both human MET (hMET) and mouse MET (mMET).
Fabs are grouped in families based on their VH CDR3 sequence. Binding of Fabs to
human and mouse MET ECD was determined by Surface Plasmon Resonance (SPR) and
by ELISA. SPR values represent the koff (s 1) . ELISA values represent the Optical Density
(OD) at 450 nm (AU, arbitrary units). Both SPR and ELISA were performed using crude
periplasmic extracts. Fab concentration in the extract was not determined. Values are the
mean of three independent measurements.
Example 3 : Chimerization of Fabs into mAbs
The cDNAs encoding the VH and VL ( κ or λ) domains of selected Fab fragments
were engineered into two separate pUPE mammalian expression vectors (U-protein
Express) containing the cDNAs encoding CH1 , CH2 and CH3 of human lgG1 or the
human CL ( κ or λ) , respectively.
Production (by transient transfection of mammalian cells) and purification (by
protein A affinity chromatography) of the resulting chimeric llama-human lgG1 molecules
was outsourced to U-protein Express. Binding of chimeric mAbs to MET was determined
by ELISA using hMET or mMET ECD in solid phase and increasing concentrations of
antibodies (0-20 nM) in solution. Binding was revealed using HRP-conjugated anti-human
Fc antibodies (Jackson Immuno Research Laboratories). This analysis revealed that all
chimeric llama-human antibodies bound to human and mouse MET with picomolar affinity,
displaying an EC
50
comprised between 0.06 nM and 0.3 nM. Binding capacity (EMAX)
varied from antibody to antibody, possibly due to partial epitope exposure in the
immobilized antigen, but was similar in the human and mouse setting. EC
50
and EMAX
values are shown in Table 9 .
Table 9 : Binding of chimeric mAbs to human and mouse MET as determined
by ELISA using immobilized MET ECD in solid phase and increasing concentrations
(0-20 nM) of antibodies in solution. EC5ovalues are expressed as nMol/L. EMAX values
are expressed as Optical Density (OD) at 450 nm (AU, arbitrary units).
We also analysed whether chimeric anti-MET antibodies bound to native human
and mouse MET in living cells. To this end, increasing concentrations of antibodies (0-100
nM) were incubated with A549 human lung carcinoma cells (American Type Culture
Collection) or MLP29 mouse liver precursor cells (a gift of Prof. Enzo Medico, University of
Torino, Strada Provinciale 142 km 3.95, Candiolo, Torino, Italy; Medico et al., Mol Biol Cell
7 , 495-504, 1996), which both express physiological levels of MET. Antibody binding to
cells was analysed by flow cytometry using phycoerythrin-conjugated anti-human lgG1
antibodies (eBioscience) and a CyAn ADP analyser (Beckman Coulter). As a positive
control for human MET binding, we used a commercial mouse anti-human MET antibody
(R&D Systems) and phycoerythrin-conjugated anti-mouse lgG1 antibodies (eBioscience).
As a positive control for mouse MET binding we used a commercial goat anti-mouse MET
antibody (R&D Systems) and phycoerythrin-conjugated anti-goat lgG1 antibodies
(eBioscience). All antibodies displayed dose-dependent binding to both human and
mouse cells with an EC
50
varying between 0.2 nM and 2.5 nM. Consistent with the data
obtained in ELISA, maximal binding ( EMAX) varied depending on antibody, but was similar
in human and mouse cells. These results indicate that the chimeric llama-human
antibodies recognize membrane-bound MET in its native conformation in both human and




values are shown in Table 10.
Table 10: Binding of chimeric mAbs to human and mouse cells as
determined by flow cytometry using increasing concentrations (0-50 nM) of
antibodies. EC5o values are expressed as nMol/L. EMAX values are expressed as %
relative to control.
Example 4 : Receptor regions responsible for antibody binding
In order to map the receptor regions recognized by antibodies binding to both
human and mouse MET (herein after referred to as human/mouse equivalent anti-MET
antibodies), we measured their ability to bind to a panel of engineered proteins derived
from human MET generated as described (Basilico et al, J Biol. Chem. 283, 21267-21227,
2008). This panel included: the entire MET ECD (Decoy MET); a MET ECD lacking IPT
domains 3 and 4 (SEMA-PSI-IPT 1-2); a MET ECD lacking IPT domains 1-4 (SEMA-PSI);
the isolated SEMA domain (SEMA); a fragment containing IPT domains 3 and 4 (IPT 3-4).
Engineered MET proteins were immobilized in solid phase and exposed to increasing
concentrations of chimeric antibodies (0-50 nM) in solution. Binding was revealed using
HRP-conjugated anti-human Fc antibodies (Jackson Immuno Research Laboratories). As
shown in Table 1 1 , this analysis revealed that 7 mAbs recognize an epitope within the
SEMA domain, while the other 4 recognize an epitope within the PSI domain.
Table 1 1 : Binding of human/mouse equivalent anti-MET antibodies to the
panel of MET deletion mutants. The MET domain responsible for antibody binding is
indicated in the last column to the right.
To more finely map the regions of MET responsible for antibody binding, we
exploited the absence of cross-reactivity between our antibodies and llama MET (the
organism used for generating these immunoglobulins). To this end, we generated a series
of llama-human and human-llama chimeric MET proteins spanning the entire MET ECD
as described (Basilico et al., J Clin Invest. 124, 3172-31 86, 2014). Chimeras were
immobilized in solid phase and then exposed to increasing concentrations of mAbs (0-20
nM) in solution. Binding was revealed using HRP-conjugated anti-human Fc antibodies
(Jackson Immuno Research Laboratories). This analysis unveiled that 5 SEMA-binding
mAbs (71 D6, 7 1C3, 7 1D4, 7 1A3, 7 1G2) recognize an epitope localized between aa 314-
372 of human MET, a region that corresponds to blades 4-5 of the 7-bladed SEMA -
propeller (Stamos et al., EMBO J. 23, 2325-2335, 2004). The other 2 SEMA-binding mAbs
(74C8, 72F8) recognize an epitope localized between aa 123-223 and 224-31 1,
respectively, corresponding to blades 1-3 and 1-4 of the SEMA -propeller. The PSI-
binding mAbs (76H10, 7 1G3, 76G7, 71G1 2) did not appear to display any significant
binding to any of the two PSI chimeras. Considering the results presented in Table 1 1 ,
these antibodies probably recognize an epitope localized between aa 546 and 562 of
human MET. These results are summarized in Table 12.
Table 12: Mapping of the epitopes recognized by human/mouse equivalent
anti-MET antibodies as determined by ELISA. Human MET ECD (hMET) or llama MET
ECD (IMET) as well as the llama-human MET chimeric proteins (CH1 -7) were immobilized
in solid phase and then exposed to increasing concentrations of mAbs.
Example 5 : HGF competition assays
The above analysis suggests that the epitopes recognized by some of the
human/mouse equivalent anti-MET antibodies may overlap with those engaged by HGF
when binding to MET (Stamos et al., EMBO J. 23, 2325-2335, 2004; Merchant et al., Proc
Natl Acad Sci USA 110 , E2987-2996, 201 3 ; Basilico et al., J Clin Invest. 124, 3172-31 86,
2014). To investigate along this line, we tested the competition between mAbs and HGF
by ELISA. Recombinant human and mouse HGF (R&D Systems) were biotinylated at the
N-terminus using NHS-LC-biotin (Thermo Scientific). MET-Fc protein, either human or
mouse (R&D Systems), was immobilized in solid phase and then exposed to 0.3 nM
biotinylated HGF, either human or mouse, in the presence of increasing concentrations of
antibodies (0-1 20 nM). HGF binding to MET was revealed using HRP-conjugated
streptavidin (Sigma-Aldrich). As shown in Table 13, this analysis allowed to divide
human/mouse equivalent anti-MET mAbs into two groups: full HGF competitors (71 D6,
71C3, 7 1D4, 7 1A3, 7 1G2), and partial HGF competitors (76H1 0 , 71G3, 76G7, 71G1 2 ,
74C8, 72F8).
Table 13: Ability of human/mouse equivalent anti-MET antibodies to compete
with HGF for binding to MET as determined by ELISA. A MET-Fc chimeric protein
(either human or mouse) was immobilized in solid phase and exposed to a fixed
concentration of biotinylated HGF (either human or mouse), in the presence of increasing
concentrations of antibodies. HGF binding to MET was revealed using HRP-conjugated
streptavidin. Antibody-HGF competition is expressed as IC
50
(the concentration that
achieves 50% competition) and IMAX (the maximum % competition reached at saturation).
As a general rule, SEMA binders displaced HGF more effectively than PSI binders.
In particular, those antibodies that recognize an epitope within blades 4 and 5 of the
SEMA -propeller were the most potent HGF competitors (71 D6, 71C3, 7 1D4, 7 1A3,
7 1G2). This observation is consistent with the notion that SEMA blade 5 contains the high
affinity binding site for the -chain of HGF (Merchant et al., Proc Natl Acad Sci USA 110,
E2987-2996, 2013). The PSI domain has not been shown to participate directly with HGF,
but it has been suggested to function as a ‘hinge’ regulating the accommodation of HGF
between the SEMA domain and the IPT region (Basilico et al., J Clin Invest. 124, 3 172-
3 186, 2014). It is therefore likely that mAbs binding to PSI (76H1 0 , 7 1G3, 76G7, 71G1 2)
hamper HGF binding to MET by interfering with this process or by steric hindrance, and
not by direct competition with the ligand. Finally, blades 1-3 of the SEMA -propeller have
been shown to be responsible for low-affinity binding of the -chain of HGF, which plays a
central role in MET activation but only partially contributes to the HGF-MET binding
strength (Stamos et al., EMBO J. 23, 2325-2335, 2004). This could explain why mAbs
binding to that region of MET (74C8, 72F8) are partial competitors of HGF.
Example 6 : MET activation assays
Due to their bivalent nature, immunoglobulins directed against receptor tyrosine
kinases may display receptor agonistic activity, mimicking the effect of natural ligands. To
investigate along this line, we tested the ability of human/mouse equivalent anti-MET
antibodies to promote MET auto-phosphorylation in a receptor activation assay. A549
human lung carcinoma cells and MLP29 mouse liver precursor cells were deprived of
serum growth factors for 48 hours and then stimulated with increasing concentrations (0-5
nM) of antibodies or recombinant HGF (A549 cells, recombinant human HGF, R&D
Systems; MLP29 cells, recombinant mouse HGF, R&D Systems). After 15 minutes of
stimulation, cells were washed twice with ice-cold phosphate buffered saline (PBS) and
then lysed as described (Longati et al., Oncogene 9 , 49-57, 1994). Protein lysates were
resolved by electrophoresis and then analysed by Western blotting using antibodies
specific for the phosphorylated form of MET (tyrosines 1234-1 235), regardless of whether
human or mouse (Cell Signaling Technology). The same lysates were also analysed by
Western blotting using anti-total human MET antibodies (Invitrogen) or anti-total mouse
MET antibodies (R&D Systems). This analysis revealed that all human/mouse equivalent
antibodies display MET agonistic activity. Some antibodies promoted MET auto
phosphorylation to an extent comparable to that of HGF (71G3, 7 1D6, 7 1C3, 7 1D4, 71A3,
7 1G2, 74C8). Some others (76H1 0 , 76G7, 71G12, 72F8) were less potent, and this was
particularly evident at the lower antibody concentrations. No clear correlation between
MET activation activity and HGF-competition activity was observed.
To obtain more quantitative data, the agonistic activity of antibodies was also
characterized by phospho-MET ELISA. To this end, A549 and MLP29 cells were serum-
starved as above and then stimulated with increasing concentrations (0-25 nM) of mAbs.
Recombinant human (A549) or mouse (MLP29) HGF was used as control. Cells were
lysed and phospho-MET levels were determined by ELISA as described (Basilico et al., J
Clin Invest. 124, 3 172-31 86, 2014). Briefly, 96 well-plates were coated with mouse ant i
human MET antibodies or rat anti-mouse MET antibodies (both from R&D Systems) and
then incubated with cell lysates. After washing, captured proteins were incubated with
biotin-conjugated anti-phospho-tyrosine antibodies (Thermo Fisher), and binding was
revealed using HRP-conjugated streptavidin (Sigma-Aldrich).
The results of this analysis are consistent with the data obtained by Western
blotting. As shown in Table 14, 71G3, 7 1D6, 71C3, 7 1D4, 7 1A3, 71G2 and 74C8 potently
activated MET, while 76H10, 76G7, 7 1G12 and 72F8 caused a less pronounced effect. In
any case, all antibodies displayed a comparable effect in human and in mouse cells.
Table 14: Agonistic activity of human/mouse equivalent anti-MET antibodies
in human and mouse cells as measured by ELISA. A549 human lung carcinoma cells
and MLP29 mouse liver precursor cells were serum-starved and then stimulated with
increasing concentrations of mAbs. Recombinant human HGF (hHGF; A549) or mouse
HGF (mHGF; MLP29) was used as control. Cell lysates were analysed by ELISA using
anti-total MET antibodies for capture and anti-phospho-tyrosine antibodies for revealing.





Example 7 : Scatter assay
To evaluate whether the agonistic activity of human/mouse equivalent anti-MET
antibodies could translate into biological activity, we performed scatter assays with both
human and mouse epithelial cells. To this end, HPAF-II human pancreatic
adenocarcinoma cells (American Type Culture Collection) and MLP29 mouse liver
precursor cells were stimulated with increasing concentrations of recombinant HGF
(human or mouse; both from R&D Systems) and cell scattering was determined 24 hours
later by microscopy as described previously (Basilico et al., J Clin Invest. 124, 3 172-3186,
2014). This preliminary analysis revealed that HGF-induced cell scattering is linear until it
reaches saturation at approximately 0.1 nM in both cell lines. Based on these HGF
standard curves, we elaborated a scoring system ranging from 0 (total absence of cell
scattering in the absence of HGF) to 4 (maximal cell scattering in the presence of 0.1 nM
HGF). HPAF-II and MLP29 cells were stimulated with increasing concentrations of
human/mouse equivalent anti-MET antibodies, and cell scattering was determined 24
hours later using the scoring system described above. As shown in Table 15, this analysis
revealed that all mAbs tested promoted cell scattering in both the human and the mouse
cell systems, with substantially overlapping results on both species. 7 1D6 and 7 1G2
displayed the very same activity as HGF; 7 1G3 and 7 1A3 were just slightly less potent
than HGF; 71C3 and 74C8 required a substantially higher concentration in order to match
the activity of HGF; 7 1D4, 76G7, 71G1 2 and 72F8 did not reach saturation in this assay.
Table 15: Biological activity of human/mouse equivalent anti-MET antibodies
as measured in a cell-based scatter assay. HPAF-II human pancreatic adenocarcinoma
cells and MLP29 mouse liver precursor cells were stimulated with increasing
concentrations of human/mouse equivalent anti-MET antibodies, and cell scattering was
determined 24 hours later using the scoring system described in the text (0, absence of
cell scattering; 4 , maximal cell scattering).
HPAF-II human pancreatic adenocarcinoma cells
MLP29 mouse liver precursor cells
Example 8 : Protection against drug-induced apoptosis
Several lines of experimental evidence indicate that HGF display a potent anti-
apoptotic effect on MET-expressing cells (reviewed by Nakamura et al., J Gastroenterol
Hepatol. 26 Suppl 1, 188-202, 201 1). To test the potential anti-apoptotic activity of
human/mouse equivalent anti-MET antibodies, we performed cell-based drug-induced
survival assays. MCF1 0A human mammary epithelial cells (American Type Culture
Collection) and MLP29 mouse liver precursor cells were incubated with increasing
concentrations of staurosporine (Sigma Aldrich). After 48 hours, cell viability was
determined by measuring total ATP concentration using the Cell Titer Glo kit (Promega)
with a Victor X4 multilabel plate reader (Perkin Elmer). This preliminary analysis revealed
that the drug concentration that induced about 50% cell death is 60 nM for MCF1 0A cells
and 100 nM for MLP29 cells. Next, we incubated MCF10A cells and MLP29 cells with the
above determined drug concentrations in the presence of increasing concentrations (0-32
nM) of anti-MET mAbs or recombinant HGF (human or mouse; both from R&D Systems).
Cell viability was determined 48 hours later as described above. The results of this
analysis, presented in Table 16, suggest that human/mouse equivalent antibodies
protected human and mouse cells against staurosporine-induced cell death to a
comparable extent. While some mAbs displayed a protective activity similar or superior to
that of HGF (71 G3, 7 1D6, 7 1G2), other molecules displayed only partial protection
(76H10, 7 1C3, 7 1D4, 7 1A3, 76G7, 71G1 2 , 74C8, 72F8), either in the human or in the
mouse cell system.
Table 16: Biological activity of human/mouse equivalent anti-MET antibodies
as measured by a cell-based drug-induced apoptosis assay. MCF1 0A human
mammary epithelial cells and MLP29 mouse liver precursor cells were incubated with a
fixed concentration of staurosporine in the the presence of increasing concentrations of
anti-MET mAbs or recombinant HGF (human or mouse), and total ATP content was
determined 48 hours later. Cell viability was calculated as % total ATP content relative to




Example 9 : Branching morphogenesis assay
HGF is a pleiotropic cytokine which promotes the harmonic regulation of
independent biological activities, including cell proliferation, motility, invasion,
differentiation and survival. The cell-based assay that better recapitulates all of these
activities is the branching morphogenesis assay, which replicates the formation of tubular
organs and glands during embryogenesis (reviewed by Rosario and Birchmeier, Trends
Cell Biol. 13, 328-335, 2003). In this assay, a spheroid of epithelial cells is seeded inside a
3D collagen matrix and is stimulated by HGF to sprout tubules which eventually form
branched structures. These branched tubules resemble the hollow structures of epithelial
glands, e.g. the mammary gland, in that they display a lumen surrounded by polarized
cells. This assay is the most complete HGF assay that can be run in vitro.
In order to test whether human/mouse equivalent anti-MET antibodies displayed
agonistic activity in this assay, we seeded LOC human kidney epithelial cells (Michieli et
al. Nat Biotechnol. 20, 488-495, 2002) and MLP29 mouse liver precursor cells in a
collagen layer as described (Hultberg et al., Cancer Res. 75, 3373-3383, 2015), and then
exposed them to increasing concentrations of mAbs or recombinant HGF (human or
mouse, both from R&D Systems). Branching morphogenesis was followed over time by
microscopy, and colonies were photographed after 5 days. Quantification of branching
morphogenesis activity was obtained by counting the number of branches for each
spheroid. As shown in Table 17, all antibodies tested induced dose-dependent formation
of branched tubules. However, consistent with the data obtained in MET auto
phosphorylation assays and cell scattering assays, 7 1D6, 7 1A3 and 7 1G2 displayed the
most potent agonistic activity, similar or superior to that of recombinant HGF.
Table 17: Branching morphogenesis assay. Cell spheroids preparations of LOC
human kidney epithelial cells or MLP29 mouse liver precursor cells were seeded in a
collagen layer and then incubated with increasing concentrations (0, 0.5, 2.5 and 12.5 nM)
of mAbs or recombinant HGF (LOC, human HGF; MLP29, mouse HGF). Branching
morphogenesis was followed over time by microscopy, and colonies were photographed
after 5 days. Branching was quantified by counting the number of branches for each
spheroid (primary branches plus secondary branches).
LOC cells
MLP29 cells
Example 10: Fine epitope mapping
In order to finely map the epitopes of MET recognized by human/mouse equivalent
anti-MET antibodies we pursued the following strategy. We reasoned that, if an antibody
generated in llamas and directed against human MET cross-reacts with mouse MET, then
this antibody probably recognizes a residue (or several residues) that is (or are)
conserved between H. sapiens and M. musculus but not among H. sapiens, M. musculus
and L. glama. The same reasoning can be extended to R. norvegicus and M. fascicularis.
To investigate along this line, we aligned and compared the amino acid sequences
of human (UniProtKB # P08581 ; aa 1-932), mouse (UniProtKB # P 16056.1 ; aa 1-931), rat
(NCBI # NP_1 13705.1 ; aa 1-931), cynomolgus monkey (NCBI # XP_005550635.2; aa 1-
948) and llama MET (GenBank # KF042853.1 ; aa 1-931) among each other. With
reference to Table 12, we concentrated our attention within the regions of MET
responsible for binding to the 7 1D6, 7 1C3, 7 1D4, 7 1A3 and 7 1G2 antibodies (aa 314-372
of human MET) and to the 76H10 and 7 1G3 antibodies (aa 546-562 of human MET).
Within the former region of human MET (aa 314-372) there are five residues that are
conserved in human and mouse MET but not in llama MET (Ala 327, Ser 336, Phe 343,
lie 367, Asp 372). Of these, four residues are also conserved in rat and cynomolgus
monkey MET (Ala 327, Ser 336, lie 367, Asp 372). Within the latter region of human MET
(aa 546-562) there are three residues that are conserved in human and mouse MET but
not in llama MET (Arg 547, Ser 553, Thr 555). Of these, two residues are also conserved
in rat and cynomolgus monkey MET (Ser 553 and Thr 555).
Using human MET as a template, we mutagenized each of these residues in
different permutations, generating a series of MET mutants that are fully human except for
specific residues, which are llama. Next, we tested the affinity of selected SEMA-binding
mAbs (71 D6, 7 1C3, 7 1D4, 71A3, 71G2) and PSI-binding mAbs (76H10 and 7 1G3) for
these MET mutants by ELISA. To this end, the various MET proteins were immobilized in
solid phase (100 ng/well in a 96-well plate) and then exposed to increasing concentrations
of antibodies (0-50 nM) solution. As the antibodies used were in their human constant
region format, binding was revealed using HRP-conjugated anti-human Fc secondary
antibody (Jackson Immuno Research Laboratories). Wild-type human MET was used as
positive control. The results of this analysis are presented in Table 18.
Table 18. The epitopes of MET responsible for agonistic antibody binding
represent residues conserved among H. sapiens, M. musculus, R. norvegicus, M.
fascicularis but not among the same species and L glama. The relevance of residues
conserved among human, mouse, rat, cynomolgus monkey but not llama MET for binding
to agonistic mAbs was tested by ELISA. Wild-type (WT) or mutant (MT) human MET ECD
was immobilized in solid phase and exposed to increasing concentrations of mAbs in
solution. Binding was revealed using anti-human Fc secondary antibodies. All binding
values were normalized to the WT protein and are expressed as % binding (EMAX)
compared to WT MET.
The results presented above provide a definite and clear picture of the residues
relevant for binding to our agonistic antibodies.
All the SEMA binders tested (71 D6, 71C3, 7 1D4, 7 1A3, 71G2) appear to bind to
an epitope that contains 2 key amino acids conserved in human, mouse, cynomolgus and
rat MET but not in llama MET lying within blade 5 of the SEMA -propeller: lie 367 and
Asp 372. In fact, mutation of Ala 327, Ser 336 or Phe 343 did not affect binding at all;
mutation of lie 367 partially impaired binding; mutation of lie 367 and Asp 372 completely
abrogated binding. We conclude that both lie 367 and Asp 372 of human MET are
important for binding to the SEMA-directed antibodies tested.
Also the PSI binders tested (76H1 0 , 7 1G3) appear to bind to a similar or the same
epitope. In contrast to the SEMA epitope, however, the PSI epitope contains only one key
amino acid also conserved in human, mouse, cynomolgus and rat MET but not in llama
MET: Thr 555. In fact, mutation of Arg 547 or Ser 553 did not affect binding at all, while
mutation of Thr 555 completely abrogated it. We conclude that Thr 555 represents the
crucial determinant for binding to the PSI-directed antibodies tested.
Example 11: Design, generation and characterization of a one-armed MET-specific
antagonistic antibody blocking the biological activity of Hepatocyte Growth Factor and
cross-reactive with human, mouse, rat and monkey MET
As the results presented so far suggest, all anti-MET antibodies described in this
document display agonistic activity, although with different potency. This depends on the
ability of the immunoglobulin molecule, which is bivalent, to stabilize the bound antigen
(MET) in a dimeric form, leading to receptor trans-phosphorylation and activation. In order
to generate a MET antagonistic antibody, also cross-reactive with human, mouse, rat and
monkey MET, we transformed a bivalent agonistic antibody selected from the above panel
(74C8) into a monovalent, one-armed form (74C8-OA). 74C8-OA consists of a single
antigen-binding fragment (Fab) fused to a complete constant domain fragment (Fc) as
described before (Merchant et al., Proc Natl Acad Sci. 110:2987-2996, 2013). The one-
armed antibody was produced in mammalian cells and gel-purified as described for the
other antibodies. The ability of 74C8-OA to bind to human, mouse, rat and monkey MET
was assessed by ELISA using a MET ECD in solid phase and increasing concentrations
of the antibody in solution. This analysis revealed that 74C8-OA binds with similar affinity
to all of these MET proteins. The binding of 74C8-OA to native MET was determined by
flow cytometry on human and mouse epithelial cells expressing MET. Cells were
incubated with increasing concentrations of the antibody, and binding was revealed by
flow cytometry analysis. The results obtained in these experiments indicated that 74C8-
OA binds to native MET on the surface of living cells. In order to assess the ability of
74C8-OA to displace human or mouse HGF, an HGF competition assay was performed
by ELISA. MET-Fc protein, either human or mouse, was immobilized in solid phase and
then exposed to biotinylated human or mouse HGF in the presence of increasing
concentrations of the antibody. HGF binding was measured by horse radish-conjugated
streptavidin. This analysis revealed that 74C8-OA is a potent displacer of HGF in both
human and mouse HGF/MET systems.
Both the agonistic and antagonistic activity of 74C8-OA were characterized by
phospho-MET ELISA on mouse and human epithelial cells. For the agonistic activity
assay, serum-starved cells were stimulated with increasing concentrations of 74C8-OA,
lysed and then adsorbed on goat anti-human MET antibody (R&D Systems) in solid
phase. Phospho-MET was revealed using a rabbit anti-pMET (Y1 234-Y1235) antibody
(Cell Signaling) and a secondary HRP-conjugated goat anti-rabbit antibody (Pierce). This
analysis revealed that the agonistic activity of 74C8-OA is negligible at all concentrations
tested. For the antagonistic activity, serum-starved mouse and human epithelial cells were
stimulated with a fixed concentration ( 100 ng/ml) of recombinant human HGF (R&D
Systems) in the presence of increasing concentrations of 74C8-OA. MET activation was
determined by phospho-MET ELISA as described above. This analysis demonstrated that
74C8-OA displays strong MET antagonistic activity by inhibiting HGF-induced MET auto
phosphorylation.
We conclude that the 74C8-OA antibody is a potent MET antagonistic antibody
that, in contrast to the MET agonist antibodies provided herein, does not display any
significant MET agonistic activity.
Example 12: The 7 1D6 MET agonistic antibody inhibits chronic inflammation-
induced colorectal fibrosis and carcinogenesis
To cast light onto the potential pro-tumorigenic effect of MET activation in a chronic
colon inflammation setting, we compared the pharmacological effect of a MET agonistic
antibody (71 D6) with that of a MET antagonistic antibody (74C8-OA) in a classic two-hit
colon carcinogenesis mouse model. To this end, we exposed 8 week-old female BALB/c
mice (Charles River) to a single i.p. injection with azoxymethane (AOM; a potent mutagen
for epithelial cells of the gastro-intestinal tract) at a dose of 12.5 mg/kg followed by three
cycles of dextran sodium sulphate (DSS; a potent inducer of colon inflammation and
ulceration) dissolved in the drinking water at a concentration of 6% (weight/volume). Each
inflammatory cycle consisted of 7 days of DSS administration followed by 14 days on
regular water. On day 8 , when the first cycle of DSS started, mice were randomized into 4
arms of 11 mice each which received respectively: (i) vehicle only (PBS); (ii) the MET
agonistic 7 1D6 antibody at a dose of 1 mg/kg ; (iii) the MET agonistic 7 1D6 antibody at a
dose of 5 mg/kg; (iv) the MET antagonistic antibody 74C8-OA at a dose of 5 mg/kg. An
additional, fifth control arm contained 7 mice that received no AOM-DSS or antibody and
served as healthy control. Mice were sacrificed 16 days after the third DSS cycle was
interrupted. At autopsy, colons were collected, washed through, and their length and
weight were determined. Following measurement, colons were cut open longitudinally and
stained with 1% Alcian Blue solution to highlight tumour masses. Tumours were counted
and photographed under a stereo-microscope. At the end of this procedure, colons were
fixed in 4% paraformaldehyde, embedded in paraffin and processed for histological
analysis. During the whole course of the experiment, mouse weight was monitored on a
regular basis, and the clinical symptoms of ulcerative colitis were assessed by
determining fecal blood, rectal bleeding and stool consistency. Quantification was
achieved using a standard scoring system used in pre-clinical models (Kim et al., J Vis
Exp. 60, pii: 3678, 201 2): each parameter scored from 0 (absence of the symptom) to 3
(maximal manifestation of the symptom). Scores relative to the single parameters were
summed together to give rise to the Disease Activity Index (DAI) ranging from 0 to 9 .
As shown in Figure 1A, exposure to DSS caused a weight loss that increased at
each cycle (cycle 1, up to 15%; cycle 2 , up to 20%; cycle 3 , up to 25%). The DAI
increased to a score of 3 or higher during cycle 1 and significantly worsened during cycles
2 and 3 , reaching values higher than 4 during the last cycle (Figure 1B). Remarkably,
animals fail to recover after the last cycle and continued to display a DAI of 3 or higher,
indicating that the inflammatory state could not be reverted at this stage. Consistent with
the idea that HGF promotes colonic mucosa integrity and inhibits inflammation, the 7 1D6
agonistic antibody reduced DSS-induced weight loss and accelerated recover, as well as
dramatically inhibited the clinical symptoms of colon inflammation throughout the
experiment as measured by DAI analysis. The 74C8-OA antagonistic antibody did not
have any effect on either body weight or DAI until cycle 2 but, consistent with the idea that
endogenous HGF may act as a natural factor against tissue injury, appeared to worsen
the clinical signs of colon inflammation at cycle 3 and after.
As determined at autopsy, DSS reduced colon length by 30% (Figure 2A), while it
increased colon specific weight (expressed as grams/cm) up to 93% (Figure 2B). Notably,
7 1D6 treatment both at 1 and 5 mg/kg prevented colon shortage limiting it to no n
significant variations, and maintained colon specific weight values very close to those of
healthy control mice. On the contrary, the 74C8-OA MET antagonistic antibody performed
similar to vehicle alone both in terms of colon length and colon specific weight.
Following length and weight measurement, colons were opened with a longitudinal
cut and stained with 1% Alcian Blue solution, as described above. Colon specimens were
analyzed by placing the flattened tissue under a stereo-microscope with their inner
(lumen) side towards the lens, and photographed. This analysis revealed that AOM/DSS
treatment resulted in the induction of a plethora of polyps at the level of the mid-colon, at
approximately half way between the cecum joint and the anus (Figure 3). Surprisingly, the
agonistic 7 1D6 antibody dramatically reduced colorectal carcinogenesis in this model,
while the antagonistic 74C8-OA antibody did not affect AOM/DSS-induced tumour
formation at all. Tumour number was assessed by counting the number of polyps that
were protruding from the otherwise flat mucosa over the entire colon. All mice exposed to
AOM/DSS displayed some tumour in the colon. However, remarkably, the 7 1D6 agonistic
antibody reduced the number of tumour masses by more than 50% (Figure 4A). Notably,
this reduction was statistically significant (p < 0.05) compared to the vehicle alone arm
both at 1 and 5 mg/kg, thus confirming the efficacy of the treatment even at the lower
dose tested. On the contrary, the antagonistic anti-MET 74C8-OA antibody did not
significantly reduce the number of tumours, thus implying that MET agonistic activity and
not just MET binding is essential for inhibiting colon carcinogenesis in the presence of
persistent inflammation. Colon images were analysed using Image J software (National
Institutes of Health) and the volume of the polyps was calculated using the formula V =
¾π ( /2)·( /2)2, where V is the volume of the polyp, and X and Y are the major and minor
dimensions of the polyp section, respectively (in mm). As shown in Figure 4B, 7 1D6
reduced not only the number but also the size of tumour masses in a dose-dependent
manner ( 1 mg/kg 50% reduction; 5 mg/kg, 25% reduction) compared to the vehicle alone
arm. Even more strikingly, 7 1D6 was very effective in decreasing total tumour burden,
reaching 77% reduction at the 1 mg/kg dose and 89% at the 5 mg/kg dose (Figure 4C).
Not less importantly, treatment with the antagonistic anti-MET 74C8-OA antibody did not
affect any of the tumour parameters measured, i.e. mean polyp number, mean tumour
volume and total tumour burden.
Following tissue processing and paraffin embedding, colon specimens were cut
using a microtome and prepared for histological and immunohistochemical analysis. First,
sections were stained with hematoxylin and eosin and examined by microscopy. This
analysis confirmed that AOM/DSS treatment caused chronic inflammation of the colonic
mucosa leading to the development of large malignant lesions (Figure 5). Histological
analysis of tumours revealed that all lesions represent high grade adenomas of the
colonic epithelium (also known as in situ carcinoma of the colon). Strikingly, the 7 1D6
antibody at both doses almost completely suppressed adenoma formation, maintaining a
normal morphology of the mucosa, substantially indistinguishable from the control group.
The antagonistic 74C8-OA antibody, on the contrary, did not affect AOM/DSS-induced
tumour formation at all.
Next, we determined whether chronic colon inflammation resulted in fibrosis. To
this end, colon sections were stained by various techniques specific for the detection of
fibrotic tissue, including the Piero Sirius red method, which highlights collagen, and ant i
alpha smooth muscle actin ( -SMA) antibodies, which specifically stain myofibroblasts.
These analyses revealed that repeated DSS administration caused the insurgence of
massive fibrosis in colonic tissue. Collagen-rich fibrotic tissue is particularly evident where
tumour masses are present (Figure 6). Remarkably, colon sections derived from animals
treated with both AOM-DSS and 7 1D6 showed a significant lower collagen deposition and
milder fibrosis at 1 mg/kg as well as at the higher dose without any evident difference
between the two. Colon sections derived from 74C8-OA-treated animals displayed an
extent of collagen deposition and fibrosis comparable to that of the vehicle alone arm. A
similar pattern of the distribution was observed with -SMA staining, with higher presence
of myofibroblasts in the vehicle alone control arm as well as in the 74C8-OA arm,
compared to mice that received 7 1D6 at either doses (Figure 7).
Colon sections were also stained for the expression of transforming growth factor
beta (TGF- ) . TGF- signalling has been demonstrated to be frequently deregulated in
human cancers, including colorectal cancer (Massague, Cell 134:251-230, 2008; Xu et al.,
Hum Mol Genet. 16(SPEC):R14-R20, 2009). While in normal or premalignant cells it
usually acts as a tumour suppressor, in advanced cancer it is frequently overexpressed
and the growth inhibitory function switch to an oncogenic one thus promoting tumour cell
proliferation and invasion (Nagaraj et al., Expert Opin Investig Drugs 19:77-91 , 201 0).
Staining of colon sections with anti-TGF- antibodies revealed that TGF- expression is
increased by the AOM-DSS treatment and particularly in tumour tissue (Figure 8).
Notably, treatment with the 7 1D6 agonistic antibody restored TGF- levels comparable to
those observed in control healthy mice both at 1 and at 5 mg/kg. In contrast, colon
sections from mice treated with the 74C8-OA antagonistic antibody displayed a TGF-
expression indistinguishable from that of the vehicle alone arm.
These data suggest that MET activation and not blockade is beneficial in chronic
inflammatory pathologies of the intestine, and that administration of a MET-activating drug
can both reduce the clinical signs of chronic colon inflammation (such as weight loss,
diarrhoea, rectal bleeding, blood in stool, colon thickening, collagen deposition,
myofibroblast proliferation and fibrosis) and suppress the development of chronic
inflammation-induced colorectal cancer. We suggest that the 7 1D6 antibody or other
similar MET agonistic antibodies may be used in the clinic to treat pathological conditions
associated with chronic colon inflammation, including colitis-associated fibrosis and
especially cancer.
Example 13: The 7 1D6 MET agonistic antibody inhibits DNA-damaaina aaent-
induced colorectal carcinogenesis
The results obtained in the AOM/DSS model suggest that MET activation using an
agonistic antibody dramatically reduces the risk of developing colorectal cancer, typically
associated with chronic inflammation of the intestine. However, colorectal cancer may
also arise from gene mutations in the epithelial cells of the colonic mucosa that
accumulate during long periods of time. The particular anatomical site of these epithelial
cells expose them to a number of agents introduced with the food or drink that may cause
DNA mutations, particularly if food is contaminated with pollutants. Furthermore,
pathological conditions of the intestine such as disbiosys or altered permeability can
enhance the occurrence of gene mutations in the colonic mucosa.
In order to determine whether MET activation via an agonistic antibody can affect
mutagenesis-promoted colorectal carcinogenesis, we tested the 7 1D6 molecule in a the
following setting. We injected 7 week-old female BALB/c mice (Charles River) with the
colon-specific mutagen AOM at a dose of 5 mg/kg once a week for 6 weeks. Starting from
day 1, mice were randomized into 2 arms of 2 1 mice each which received treatment with
7 1D6 (at a dose of 5 mg/kg) or vehicle only (PBS). Antibody was administered two times a
week by i.p. injection. An additional, third control arm contained 7 mice that received no
AOM or antibody and served as healthy control. Mice were sacrificed 8 weeks after the
last AOM injection, i.e. 14 weeks after the experiment started. At autopsy, colons were
collected and washed through. Explanted colons were measured using a ruler and
weighed. Following measurements, colons were cut open longitudinally to expose tumour
masses. Tissues were stained ex vivo with a 1% Alcian Blue solution in order to highlight
tumour borders. Polyps were counted and photographed under a stereo-microscope. At
the end of this procedure, colons were fixed in 4% paraformaldehyde, embedded in
paraffin and processed for histological analysis.
In contrast to AOM/DSS, and consistent with the absence of inflammation, AOM
alone did not affect colon length (Figure 9A) or specific weight (Figure 9B) compared to
control mice. 7 1D6 treatment also did not change significantly either parameter. However,
AOM-induced mutagenesis did result in the development of colorectal cancer, although to
a reduced extent compared to AOM/DSS in terms of both incidence (Figure 10A) and
number (Figure 10B). This is consistent with the idea that chronic inflammation boosts
tumour progression in many organs, including the intestine. Interestingly, treatment with
the 7 1D6 agonistic antibody significantly inhibited AOM-promoted cancer: in fact, both
tumour incidence (Figure 10A) and number (Figure 10B) decreased by approximately
60% in the arm receiving 7 1D6.
Figure 11 shows two representative images of explanted colons for each arm.
Colon samples were stained using a 1% Alcian Blue solution. The arrows indicate
macroscopically evident tumour masses. Colon sections were then processed for
histology. This analysis indicated that the polips observed under the stereo-microscope
are low grade adenomas, therefore less malignant than those observed in the AOM/DSS
model.
Example 14: Reduction of colonic inflammation by MET agonist antibodies
We tested whether agonistic anti-MET antibodies could reduce intestinal
inflammation in a mouse model, since intestinal (colorectal) inflammation is a major risk
factor in developing colorectal cancer. To this end, we exposed 7 week-old female BALB/c
mice (Charles River) to dextran sodium sulphate (DSS) in the drinking water for 10 days.
On day 10 , DSS treatment was interrupted and mice were put back on normal water.
Starting from day 1, mice were randomized into 7 arms of 7 mice each which received
treatment with 7 1G3, 7 1D6, 7 1G2 (at a dose of 1 mg/kg or 5 mg/kg) or vehicle only (PBS).
Antibodies were administered three times a week by i.p. injection. An additional, eighth
control arm contained 7 mice that received no DSS or antibody and served as healthy
control. Mice were sacrificed on day 12 , i.e. 2 days after DSS administration was
interrupted. At autopsy, colons were collected, washed through, and their length was
determined using a ruler. Following measurement, colons were embedded in paraffin and
processed for histological analysis.
During the whole course of the experiment, mouse weight was monitored on a
regular basis, and the clinical symptoms of intestinal inflammation were assessed by
determining faecal blood, rectal bleeding and stool consistency. Quantification was
achieved using a standard scoring system used in pre-clinical models (Kim et al., J Vis
Exp. 60, pii: 3678, 201 2): each parameter scored from 0 (absence of the symptom) to 3
(maximal manifestation of the symptom). Scores relative to the single parameters were
summed together to give rise to the Disease Activity Index (DAI) ranging from 0 to 9 .
As shown in Figure 12 , exposure to DSS in the PBS arm caused a weight loss of
up to 25%; the DAI increased to a score of 4 or higher; and the length of the colon was
reduced by up to 40%. Remarkably, all antibodies analyzed reversed these effects in a
dose-dependent fashion, displaying significant activity already at the lower dose tested.
7 1D6 was the most potent antibody: after a transient decline, it brought body weight back
at normal values, comparable to those observed in the PBS group; it curbed the DAI
increase, substantially inhibiting all the clinical symptoms; and it prevented colon
shortage, limiting it to negligible variations.
Colon sections were stained with hematoxylin and eosin and examined by
microscopy. As shown in Figure 13 , DSS administration caused profound damage to the
colonic mucosa. The epithelial layer appeared eroded and infiltrated with lymphocytes.
The colonic mucosa was disseminated with cryptic abscess sites and was heavily
colonized by foamy macrophages, responsible for tissue destruction. Peri-visceral lymph
nodes appeared enlarged. The muciparous glands were characterized by atrophy and
displayed marked mucinous depletion, which was substituted with inflammatory infiltrate
including foamy macrophages, lymphocytes and neutrophils. Several ulcers were visibly
invaded by granulocytic or macrophage exudate, leading to the total disappearance of the
glandular component. Remarkably, mice treated with both DSS and agonistic anti-MET
antibodies displayed much milder symptoms of degeneration and inflammation.
Specifically, elements of acute inflammation were absent, including macrophages and
granulocytes; the mucosa appeared only marginally injured, displaying sparse glandular
distortion and rarefaction; mucin secretion was restored, and erosions and ulcers were
completely absent. Although these protective effects were dose-dependent in all antibody
groups, they were already evident at 1 mg/kg, indicating that the concentrations of
antibodies reached with this dose are very close to saturation. In this model as well, the
most effective antibody appeared to be 7 1D6, though all tested agonist antibodies were
effective.
Conclusion
We conclude that treatment with an HGF-MET agonist (in this case a MET
agonistic antibody) can be beneficial in both the treatment of colorectal cancer associated
with chronic inflammation, and also in the inhibition of tumours arising from mutations in
the colonic tissue. Agonist antibody 7 1D6 has been demonstrated to be particularly
effective in treating these conditions. Other MET agonist antibodies described herein (for
example 7 1G3 and 7 1G2) also exhibit a potent ability to reduce intestinal inflammation
comparable to 7 1D6 and will therefore provide similar therapeutic and preventative
effects.
Moreover, the results herein demonstrate that MET agonists are more effective at
treating (colorectal) cancer than the native MET ligand HGF. Yamaji et at. Oncology
Reports 26: 335-341 , 201 1 (incorporated herein by reference) describe administering
HGF to mice in similar models to those described herein. However, HGF is not as
effective as MET agonists such as anti-MET agonist antibodies - for example, HGF only
reduces tumour incidence in AOM-treated mice from 65% to about 30% (Yamaji et at,
Table I), compared to MET agonist antibodies which reduce tumour incidence to less than
20% (Figure 10).
We suggest that treatment with MET agonists, particularly MET agonist antibodies
such as 7 1D6, may be used in the clinic for reducing the development of colorectal
tumours in those individuals predisposed to colorectal cancer, for example in patients
affected by familial adenomatous polyposis (FAP; characterized by APC or MUTYH gene
mutations) or by other genetic syndromes, as well as those predisposed to colorectal
cancer as a result of inflammatory bowel conditions.
Claims
1. A method of treating cancer comprising administering to a subject in need thereof
an HGF-MET agonist.
2 . The method of claim 1, wherein the cancer is colorectal cancer.
3 . The method of claim 1 or claim 2 , wherein the subject has been identified as at
increased risk of colorectal cancer.
4 . A method of treating colorectal fibrosis, comprising administering to a subject an
HGF-MET agonist.
5 . The method of any one of claims 1-4, wherein the subject has been diagnosed
with colorectal inflammation prior to administration of the HGF-MET agonist.
6 . The method of any one of claims 1-5, wherein the subject has inflammatory bowel
disease, optionally ulcerative colitis or Crohn’s disease.
7 . The method of any one of claims 1-6, wherein the subject has a family history of
familial adenomatous polyposis (FAP).
8 . The method of any one of claims 1-7, wherein the HGF-MET agonist is
administered at a dose in the range from 0.1-1 0 mg/kg per dose.
9 . The method of any one of claims 1-8, wherein the HGF-MET agonist is
administered at a dose in the range from 0.5-1 0 mg/kg, optionally from 1-5 mg/kg.
10 . The method of any one of claims 1-9 wherein the HGF-MET agonist is
administered at a dose of 1 mg/kg or 5 mg/kg.
11. The method according to any one of claims 1- 10 , wherein the HGF-MET agonist is
administered at least once per week, optionally 1-3 times per week, optionally
twice per week.
12 . The method according to any one of claims 1-1 1, wherein the treatment is
prophylactic treatment.
13 . The method according to any one of claims 1-1 1, wherein the treatment is
therapeutic treatment.
14 . An HGF-MET agonist for use in a method according to any one of claims 1- 13 .
15 . A pharmaceutical composition for use in a method according to any one of claims
1- 13 , wherein the pharmaceutical composition comprises an HGF-MET agonist
and a pharmaceutically acceptable excipient or carrier.
16 . A method, HGF-MET agonist for use or pharmaceutical composition for use
according to any preceding claim, wherein the HGF-MET agonist is a full agonist
of MET.
17. A method, HGF-MET agonist for use or pharmaceutical composition for use
according to any preceding claim wherein, wherein the HGF-MET agonist is an
anti-MET agonist antibody or antigen-binding fragment thereof.
18. A method, antibody for use or pharmaceutical composition for use according to
claim 17 wherein the anti-MET antibody or antigen-binding fragment thereof binds
to the SEMA domain of MET, optionally blades 4-5 of the SEMA -propeller.
19. A method, antibody for use or pharmaceutical composition for use according to
claim 17 or claim 18 , wherein the anti-MET antibody or antigen-binding fragment
thereof binds to an epitope comprising residue Ile367 and/or Asp372 of MET,
optionally comprising both residue Ile367 and Asp372 of MET.
20. A method, antibody for use or pharmaceutical composition for use according to
claim 17 wherein the anti-MET antibody or antigen-binding fragment thereof binds
to the PSI domain of MET, optionally binds an epitope between residues 546 and
562 of MET.
2 1 . A method, antibody for use or pharmaceutical composition for use according to
claim 17 or claim 20, wherein the anti-MET antibody or antigen-binding fragment
thereof binds to an epitope comprising residue Thr555 of MET.
22. A method, antibody for use or pharmaceutical composition for use according to
any one of claims 17-19, wherein the anti-MET agonist antibody or antigen-binding
fragment comprises the combination of VH CDR1 , CDR2 and CDR3 sequences
and VL CDR1 , CDR2 and CDR3 sequences of 7 1D6 or of 7 1G2.
23. A method, antibody for use or pharmaceutical composition for use according to
claim 22 wherein the anti-MET agonist antibody or antigen-binding fragment
comprises a VH domain at least 90% identical to SEQ ID No 163 and/or comprises
a VL domain at least 90% identical to SEQ ID No 164 .
24. A method, antibody for use or pharmaceutical composition for use according to
any one of claims 17-23 wherein the anti-MET agonist antibody is an lgG4
antibody.
25. A method, antibody for use or pharmaceutical composition for use according to
any one of claims 17-24 wherein the anti-MET agonist antibody is 7 1D6.
26. A method of treating colorectal cancer in a subject, comprising administering to the
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